Mood Disorders

Study Notes

SECTION 1: BIPOLAR DISORDER

1.1 Epidemiology

Key Indian data:

• NMHS (2016): mood disorders prevalence ~5.25% (includes depression)
• Urban > rural prevalence in most studies
• Significant treatment gap (>70% for mood disorders)

1.2 Classification: BP-I vs BP-II vs Cyclothymia

Swipe to compare →

1.3 Clinical Features of Mania: DIGFAST

DSM-5 Criteria for Manic Episode:

• Abnormally and persistently elevated, expansive, or irritable mood AND abnormally and persistently increased goal-directed activity or energy
• Duration: >= 7 days (or any duration if hospitalization required)
• At least 3 of DIGFAST symptoms (4 if mood is only irritable)
• Marked functional impairment, psychotic features, or hospitalization
• Not attributable to substance/medical condition

1.4 Hypomania vs Mania

1.5 Mixed Features (DSM-5 Specifier)

DSM-5 replaced the old "mixed episode" (DSM-IV) with a specifier that can be applied to either manic/hypomanic or depressive episodes.

Manic/hypomanic episode with mixed features (>= 3 depressive symptoms):

• Depressed mood, diminished interest, psychomotor retardation, fatigue, worthlessness/guilt, suicidal ideation

Depressive episode with mixed features (>= 3 manic/hypomanic symptoms):

• Elevated mood, grandiosity, pressured speech, flight of ideas, increased energy/activity, decreased need for sleep, risk-taking

Clinical significance:

• Mixed features = higher suicide risk
• Mixed features = poorer response to antidepressants (may worsen)
• Valproate and atypical antipsychotics preferred over lithium for mixed presentations
• Mixed features may predict bipolar course in unipolar depression patients

1.6 Rapid Cycling

Definition: >= 4 mood episodes (any combination of mania, hypomania, depression) in a 12-month period. Episodes demarcated by either remission (>= 2 months) or switch to opposite polarity.

Risk factors:

• Female sex (more common in women)
• Hypothyroidism (must screen thyroid function)
• Antidepressant use (classic trigger, particularly TCAs, less so SSRIs)
• Substance use
• BP-II > BP-I
• Neurological conditions

Management considerations:

• Withdraw antidepressants
• Optimize mood stabilizers (valproate often preferred)
• Check and correct thyroid function
• Lithium less effective in rapid cycling than in classic episodic BPAD
• Consider combination mood stabilizers

1.7 Course and Outcome

Kraepelin's Original Observations

• Kraepelin (1921) described the longitudinal course extensively
• Noted increasing frequency of episodes over time with shortening of inter-episode intervals
• Recognized that some patients achieved full inter-episode recovery while others developed chronic residual symptoms

Modern Course Data

Prognostic Factors

1.8 Genetics of Bipolar Disorder

Key genes/loci:

• CACNA1C, voltage-gated calcium channel (shared with schizophrenia)
• ANK3, ankyrin G, involved in axon initial segment function
• CLOCK genes, circadian rhythm (CLOCK, ARNTL, PER3, CRY1)
• BDNF, Val66Met polymorphism associated with bipolar risk
• DISC1, Disrupted in Schizophrenia 1 (shared with schizophrenia)
• DGKH, diacylglycerol kinase eta
• NRG1, neuregulin 1 (shared with schizophrenia)

Genetic overlap:

• Bipolar shares more genetic architecture with schizophrenia than with unipolar depression
• Cross-Disorder Group of the PGC identified shared loci across bipolar, schizophrenia, MDD, ADHD, and ASD
• This supports a dimensional rather than categorical view of psychosis spectrum

1.9 Neurobiology of Bipolar Disorder

Kindling Model (Post & Weiss)

• Initial episodes require environmental stressors (psychosocial triggers)
• Repeated episodes lead to neurobiological sensitization
• Later episodes become increasingly autonomous (occur without clear triggers)
• Parallels seizure kindling in epilepsy
• Supports early and aggressive treatment to prevent progression
• Explains why inter-episode intervals decrease over time

Circadian Rhythm Disruption

• CLOCK gene polymorphisms associated with bipolar risk
• Social rhythm disruption can trigger episodes (Ehlers et al., Social Zeitgeber Theory)
• Sleep deprivation can trigger mania
• Light therapy effective in bipolar depression
• Melatonin pathway abnormalities documented
• Interpersonal and Social Rhythm Therapy (IPSRT) targets this mechanism

Mitochondrial Dysfunction

• Altered mitochondrial function in bipolar disorder
• Decreased ATP production, altered calcium signaling
• Explains multi-system involvement (brain, kidney, thyroid)
• Lactate elevation in brain imaging studies
• mtDNA mutations and deletions described
• Lithium has mitochondrial protective effects (one proposed mechanism)

Other Neurobiological Models

• Monoamine dysregulation: Catecholamine excess in mania, deficit in depression (oversimplified but foundational)
• Second messenger systems: Abnormal phosphoinositide signaling, PKC overactivity in mania
• Neuroinflammation: Elevated pro-inflammatory cytokines (IL-6, TNF-alpha) in mood episodes
• Glutamate: Elevated in mania, altered in depression
• HPA axis: Cortisol dysregulation, dexamethasone non-suppression
• Neuroplasticity: Reduced BDNF, hippocampal volume loss, prefrontal cortical thinning

SECTION 2: BIPOLAR DISORDER MANAGEMENT

2.1 Lithium

Mechanism of Action

• GSK-3beta inhibition, the most well-established mechanism; GSK-3beta is involved in apoptosis, circadian regulation, neurogenesis
• Inositol depletion, lithium inhibits inositol monophosphatase, reducing phosphoinositide signaling (Berridge hypothesis)
• Neuroprotection, increases Bcl-2 (anti-apoptotic), increases gray matter volume
• Modulates glutamate, reduces excitatory glutamatergic transmission
• Serotonergic enhancement, increases tryptophan uptake, enhances 5-HT release
• Anti-suicidal effect, specific to lithium, not shared by other mood stabilizers

Therapeutic Range and Monitoring

Monitoring Schedule

Side Effects

Early/common:

• Fine tremor (beta-blockers can help)
• Polyuria/polydipsia (nephrogenic diabetes insipidus, lithium impairs aquaporin-2)
• GI upset (nausea, diarrhea)
• Weight gain
• Cognitive dulling ("lithium fog")
• Acne, psoriasis exacerbation

Long-term:

• Hypothyroidism (up to 20-30%, more in women; treat with levothyroxine, do NOT stop lithium)
• Nephrogenic diabetes insipidus (reduced concentrating ability; amiloride may help)
• Chronic kidney disease (controversial; risk increases with duration; monitor eGFR)
• Hyperparathyroidism/hypercalcemia (monitor calcium)
• Cardiac, T-wave flattening/inversion, sinus node dysfunction (rare)
• Ebstein's anomaly, cardiac teratogenicity (1:1000 risk, much lower than historically feared but still significant; relative risk ~20-40x)

Lithium Toxicity

Management of lithium toxicity:

1. STOP lithium immediately
2. IV normal saline (0.9% NaCl), aggressive hydration
3. Monitor serum lithium levels every 2-4 hours
4. Monitor renal function, electrolytes
5. Correct dehydration and sodium depletion
6. Avoid diuretics (especially thiazides, increase lithium reabsorption)
7. Hemodialysis if: level >4.0 mEq/L, level >2.5 with severe symptoms, renal failure, deteriorating despite supportive care
8. Whole bowel irrigation if recent ingestion of sustained-release preparation
9. Monitor for rebound, redistribution from tissues can cause level to rise again after dialysis

Common precipitants of toxicity:

• Dehydration (vomiting, diarrhea, fever, hot weather)
• NSAIDs (reduce renal clearance)
• ACE inhibitors/ARBs
• Thiazide diuretics (NOT loop diuretics, loop diuretics are safer)
• Reduced sodium intake
• Renal impairment
• Drug interactions

2.2 Valproate (Sodium Valproate / Divalproex)

Mechanism

• Enhances GABAergic transmission (inhibits GABA transaminase, enhances GABA synthesis)
• Blocks voltage-gated sodium channels
• Inhibits histone deacetylase (HDAC), epigenetic effects
• Modulates PKC signaling

Therapeutic Range

• 50-125 mcg/mL for acute mania
• Trough levels

Monitoring

• LFTs at baseline and periodically (first 6 months critical)
• FBC and platelets (thrombocytopenia)
• Coagulation screen
• Amylase/lipase if abdominal symptoms
• Weight, metabolic parameters
• Menstrual history in women

Side Effects

• Hepatotoxicity, idiosyncratic, highest risk in children <2 years on polytherapy; monitor LFTs
• Pancreatitis, rare but potentially fatal
• PCOS/menstrual irregularities, weight gain, hyperandrogenism, menstrual dysfunction; mechanism involves enzyme induction affecting androgen metabolism
• Teratogenicity, NEURAL TUBE DEFECTS (spina bifida ~1-2%), decreased IQ in offspring (8-9 points), higher rate of autism; absolute contraindication in pregnancy/women of childbearing age per many recent guidelines
• Thrombocytopenia, dose-related
• Weight gain, significant
• Tremor, hair loss (usually reversible), GI upset
• Hyperammonemia, can occur without hepatic dysfunction; may present as confusion

Valproate in Women of Childbearing Age

2.3 Carbamazepine

Mechanism

• Voltage-gated sodium channel blocker (primary mechanism)
• Also affects calcium channels
• Reduces glutamate release

Key Pharmacological Features

• Autoinduction, carbamazepine induces its own metabolism (CYP3A4); levels drop over first 2-4 weeks; need to recheck levels and often increase dose
• Potent CYP inducer, induces CYP3A4, CYP2C9, CYP1A2; reduces levels of many drugs (OCPs, warfarin, other anticonvulsants, antipsychotics)
• Therapeutic level: 4-12 mcg/mL

HLA-B*1502 Screening

• HLA-B*1502 allele associated with carbamazepine-induced Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN)
• Highest prevalence in Southeast Asian populations (Han Chinese, Thai, Malaysian, Indian)
• FDA mandates screening before prescribing in at-risk populations
• If positive, DO NOT prescribe carbamazepine (or oxcarbazepine)

Side Effects

• CNS: dizziness, ataxia, diplopia, drowsiness
• Hyponatremia (SIADH)
• Agranulocytosis/aplastic anemia (rare but serious, monitor FBC)
• Hepatotoxicity
• SJS/TEN (see HLA-B*1502 above)
• Teratogenic (NTDs, but less than valproate)

Drug Interactions (major exam topic)

• Reduces levels of: haloperidol, olanzapine, clozapine, lamotrigine, oral contraceptives, warfarin, theophylline, doxycycline, valproate
• Levels increased by: erythromycin, cimetidine, fluoxetine, fluvoxamine, grapefruit juice
• Levels decreased by: phenytoin, phenobarbital

2.4 Lamotrigine

Key Features

• Primary role: bipolar depression prevention (maintenance)
• NOT effective for acute mania
• Effective for preventing depressive relapses in BPAD
• Glutamate modulator (reduces glutamate release via sodium channel blockade)

Titration: SJS Risk (CRITICAL)

• Must titrate slowly, rapid titration increases SJS/TEN risk
• Standard titration: 25mg/day weeks 1-2 → 50mg/day weeks 3-4 → 100mg/day week 5 → target 200mg/day by week 6-7
• If co-prescribed with valproate (which DOUBLES lamotrigine levels): halve the titration rate, start at 12.5mg
• If co-prescribed with carbamazepine (which halves lamotrigine levels): may need higher doses

Side Effects

• SJS/TEN, risk highest in first 8 weeks, with rapid titration, and with concurrent valproate
• Rash (any rash during titration = STOP and evaluate)
• Headache, dizziness, nausea
• Insomnia
• Generally well-tolerated, no weight gain, no cognitive dulling
• Favorable metabolic profile

2.5 Atypical Antipsychotics in Bipolar Disorder

2.6 Acute Mania: Treatment Algorithm

Step 1: Assess severity, rule out medical causes, assess safety

• Discontinue antidepressants
• Check substance use, thyroid, medical causes

Step 2: First-line pharmacotherapy

• Mild-moderate mania: Lithium or valproate monotherapy
• Severe mania/psychotic mania: Atypical antipsychotic (quetiapine, olanzapine, aripiprazole, risperidone) + lithium/valproate
• Agitation: Short-term benzodiazepines (lorazepam) + antipsychotic

Step 3: If inadequate response (2-4 weeks):

• Switch to alternative first-line agent
• Combine lithium + valproate
• Combine mood stabilizer + atypical antipsychotic

Step 4: Treatment-resistant mania:

• ECT (highly effective, especially with catatonic features or life-threatening mania)
• Clozapine (limited evidence but used in refractory cases)

2.7 Bipolar Depression: Management (HIGH-YIELD EXAM TOPIC)

First-line options:

1. Quetiapine monotherapy (300mg, the BOLDER trials)
2. Lithium monotherapy (evidence moderate)
3. Lamotrigine (better for prevention than acute treatment, but used)
4. Lurasidone (with or without lithium/valproate)
5. Cariprazine (1.5mg, recent FDA approval)
6. Olanzapine-fluoxetine combination (OFC)

If adding antidepressant (not first-line):

• ALWAYS combine with mood stabilizer
• SSRIs or bupropion preferred (lower switch risk)
• AVOID TCAs and SNRIs (higher switch risk)
• Short duration, withdraw antidepressant as soon as depression remits

Other options:

• ECT, effective for severe/refractory bipolar depression, psychotic features, suicidality
• Interpersonal and Social Rhythm Therapy (IPSRT)
• CBT adapted for bipolar

2.8 Maintenance Treatment

Goal: Prevent relapse of both manic and depressive episodes

Lithium remains the gold standard for maintenance, especially for classical euphoric mania, strong family history, good inter-episode functioning. Its anti-suicidal effect is unique and well-established (Cipriani et al., 2013 meta-analysis).

SECTION 3: DEPRESSION

3.1 Epidemiology

3.2 Diagnostic Criteria

ICD-11 Depressive Episode

Core symptoms (at least 1 required):

1. Depressed mood
2. Diminished interest or pleasure (anhedonia)

Accessory symptoms:

1. Reduced concentration and attention
2. Reduced self-esteem and self-confidence
3. Ideas of guilt and unworthiness
4. Bleak and pessimistic views of the future
5. Ideas or acts of self-harm or suicide
6. Disturbed sleep
7. Diminished appetite

Severity grading:

• Mild: Core + enough accessory for minimum of 5 total; mild functional impairment
• Moderate: Core + enough for minimum of 6-7 total; considerable difficulty in functioning
• Severe: Core + most accessory symptoms; marked distress/agitation or retardation; major functional impairment

DSM-5 Major Depressive Episode: SIG E CAPS + Depressed Mood

Five or more of the following for >= 2 weeks (must include depressed mood or anhedonia):

3.3 Subtypes of Depression

Melancholic Features

• Loss of pleasure in almost all activities (distinct quality of depressed mood, qualitatively different from grief)
• Lack of reactivity to pleasurable stimuli
• Worse in the morning (diurnal variation)
• Early morning awakening (>2 hours before usual)
• Marked psychomotor retardation or agitation
• Significant anorexia or weight loss
• Excessive guilt
• Better response to biological treatments (TCAs, ECT)
• Strong HPA axis dysregulation

Atypical Features

• Mood reactivity (mood brightens in response to positive events), required criterion
• Significant weight gain or increased appetite ("comfort eating")
• Hypersomnia (leaden paralysis)
• Long-standing pattern of interpersonal rejection sensitivity
• Better response to MAOIs and SSRIs than TCAs
• More common in BP-II depression

Psychotic Features (Depression with Psychotic Symptoms)

• Delusions and/or hallucinations during depressive episode
• Mood-congruent: themes of guilt, worthlessness, disease, death, nihilism, punishment (Cotard syndrome, nihilistic delusions)
• Mood-incongruent: persecutory, referential, thought insertion/broadcasting (worse prognosis)
• Requires antidepressant + antipsychotic OR ECT
• Antidepressant monotherapy inadequate
• ECT highly effective

Seasonal Affective Disorder (SAD)

• Recurrent episodes with seasonal pattern (typically winter)
• Atypical features common (hypersomnia, weight gain, carbohydrate craving)
• Light therapy (10,000 lux for 30 min each morning) is first-line
• SSRIs also effective
• Latitude-dependent prevalence

Peripartum Depression

• Onset during pregnancy or within 4 weeks postpartum (DSM-5 specifier), clinically, up to 1 year recognized
• Prevalence: 10-15% of pregnancies
• Screen using Edinburgh Postnatal Depression Scale (EPDS)
• Risk factors: prior depression, lack of social support, unplanned pregnancy, domestic violence
• Treatment: psychotherapy first-line for mild-moderate; SSRIs (sertraline preferred, low breast milk transfer) for moderate-severe
• Brexanolone (IV allopregnanolone), FDA approved for postpartum depression (2019)
• Zuranolone, oral neurosteroid, FDA approved 2023

3.4 Biological Basis of Depression

Monoamine Hypothesis (Classic)

• Depression results from deficiency of serotonin (5-HT), norepinephrine (NE), and/or dopamine (DA)
• Evidence: reserpine causes depression; antidepressants increase monoamine availability; tryptophan depletion can trigger relapse
• Limitations: antidepressants increase monoamines within hours, but clinical effect takes weeks; direct monoamine depletion does not consistently cause depression in healthy subjects

HPA Axis Dysregulation

• Hyperactivity of HPA axis in depression
• Elevated cortisol levels, enlarged adrenals
• Dexamethasone non-suppression (DST, ~50% sensitivity, poor specificity)
• CRH hypersecretion
• Glucocorticoid receptor resistance
• Chronic stress → HPA dysregulation → hippocampal damage → perpetuation of depression

Neuroplasticity and BDNF

• Brain-Derived Neurotrophic Factor (BDNF) reduced in depression
• Reduced hippocampal volume (neuroimaging studies)
• Antidepressants increase BDNF and promote neurogenesis
• Stress reduces neuroplasticity; antidepressants reverse this
• "Neuroplasticity hypothesis", depression as a disorder of synaptic plasticity

Neuroinflammation

• Elevated pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha, CRP) in depression
• Inflammatory conditions (RA, IBD, MS) have high depression comorbidity
• Interferon-alpha treatment causes depression in ~30% of patients
• Anti-inflammatory agents (celecoxib, minocycline) show antidepressant effects in trials
• Links inflammation → tryptophan degradation via IDO enzyme → reduced serotonin

Glutamate Model

• Glutamate/GABA imbalance in depression
• Ketamine (NMDA antagonist) produces rapid antidepressant effects
• Supports role of glutamatergic dysfunction
• Esketamine (intranasal), FDA approved for TRD

SECTION 4: TREATMENT-RESISTANT DEPRESSION (TRD)

4.1 Definition

TRD = failure to achieve adequate response after >= 2 adequate antidepressant trials from different pharmacological classes, each at adequate dose and duration (>= 6-8 weeks at therapeutic dose).

"Adequate trial" means:

• Therapeutic dose reached
• Minimum 6-8 weeks at therapeutic dose
• Confirmed adherence

Pseudo-resistance (rule out first):

• Inadequate dose or duration
• Non-adherence
• Misdiagnosis (bipolar depression, medical cause, substance use, personality disorder)
• Comorbidity not addressed (anxiety, substance use, medical illness)

4.2 TRD Staging

Thase-Rush Staging Model

Massachusetts General Hospital (MGH) Staging Model

• Quantitative scoring system
• Points assigned for: number of failed trials, optimization attempts, augmentation trials, ECT
• More granular than Thase-Rush
• Better for research quantification

4.3 TRD Management Algorithm

Step 1, Optimization:

• Ensure current antidepressant is at maximum tolerated dose
• Ensure adequate duration (>= 6-8 weeks at therapeutic dose)
• Confirm adherence
• Address comorbidities

Step 2, Switching:

• Switch to a different class (SSRI → SNRI → TCA → MAOI)
• Within-class switch if partial response (e.g., escitalopram → sertraline)
• Switching preferred when there is NO response to current agent

Step 3, Augmentation:

• Lithium augmentation, most evidence-based augmentation strategy; 0.6-0.8 mEq/L; response in 2-4 weeks
• Atypical antipsychotic augmentation, aripiprazole (2-5mg), quetiapine (50-300mg), olanzapine (2.5-10mg), brexpiprazole, cariprazine
• Thyroid augmentation, T3 (liothyronine 25-50 mcg/day) even in euthyroid patients; better evidence than T4
• Augmentation preferred when there IS partial response to current agent

Step 4, Combination:

• SSRI/SNRI + mirtazapine ("California rocket fuel" = venlafaxine + mirtazapine)
• SSRI/SNRI + bupropion
• Avoid SSRI + MAOI (serotonin syndrome)

Step 5, Esketamine (Spravato):

• Intranasal esketamine (FDA approved 2019 for TRD)
• Used with concurrent oral antidepressant
• Must be administered in certified healthcare settings (REMS program)
• Monitoring for 2 hours post-administration
• Rapid onset (within hours to days)

Step 6, ECT:

• Gold standard for severe/refractory depression
• 70-90% response rate in TRD
• Bilateral > unilateral for efficacy (but more cognitive side effects)
• Indicated especially for: psychotic depression, severe suicidality, catatonia, treatment resistance, pregnancy (relatively safe)

Step 7, Neuromodulation and emerging:

• rTMS, repetitive Transcranial Magnetic Stimulation; left DLPFC high-frequency stimulation; FDA approved; 4-6 week course
• VNS, Vagus Nerve Stimulation; implanted device; FDA approved for chronic TRD
• DBS, Deep Brain Stimulation; experimental; targets include subcallosal cingulate (Cg25), nucleus accumbens
• Psilocybin, emerging evidence for TRD; phase II trials promising; not yet approved

SECTION 5: DEPRESSION IN THE ELDERLY

5.1 Vascular Depression Hypothesis (Alexopoulos)

• Late-onset depression (>60 years) often associated with cerebrovascular disease
• White matter hyperintensities on MRI correlate with depression severity
• Vascular risk factors (hypertension, diabetes, smoking) increase depression risk
• Executive dysfunction prominent
• Poor response to antidepressants compared to early-onset depression
• Higher risk of progression to dementia
• "Depression-executive dysfunction syndrome", apathy, psychomotor retardation, poor insight

5.2 Pseudodementia vs Dementia

5.3 Management in Elderly

Principles:

• "Start low, go slow, but go", lower starting doses, slower titration, but aim for therapeutic doses
• SSRIs preferred (escitalopram, sertraline, fewer interactions)
• Avoid TCAs, anticholinergic effects (confusion, urinary retention, falls, cardiac), orthostatic hypotension
• Avoid benzodiazepines (falls, confusion, dependence)
• Mirtazapine useful (appetite stimulation, sedation can help insomnia)
• Consider drug interactions (elderly on multiple medications)
• Monitor sodium (SSRIs can cause SIADH/hyponatremia, higher risk in elderly)
• ECT safe and effective in elderly, may be preferred for severe depression
• Psychotherapy effective, CBT, IPT, problem-solving therapy

SECTION 6: SUICIDE

6.1 Epidemiology: India

6.2 Risk Factors: SAD PERSONS

Additional risk factors:

• Family history of suicide
• Access to lethal means (firearms, pesticides)
• Recent discharge from psychiatric hospitalization (first 1-4 weeks = highest risk)
• Hopelessness (Beck Hopelessness Scale, more predictive than depression severity)
• Impulsivity/aggression traits
• LGBTQ+ youth
• Recent loss (bereavement, relationship, financial)

6.3 Assessment

Columbia Suicide Severity Rating Scale (C-SSRS)

• Standardized, FDA-endorsed tool
• Assesses suicidal ideation (types 1-5) and suicidal behavior (types 1-5)
• Ideation severity: wish to be dead → non-specific active suicidal thoughts → active ideation with method → active ideation with intent → active ideation with plan and intent
• Behavior: preparatory acts → aborted attempt → interrupted attempt → actual attempt → completed suicide
• Can track changes over time

Assessment Framework (every evaluation should include)

1. Ideation: Passive ("wish I were dead") vs active ("want to kill myself")
2. Plan: Specific method? Timeframe?
3. Means: Access to method? (firearms, medications, pesticides)
4. Intent: How strong is the desire? What are the reasons for living?
5. Preparedness: Giving away possessions, writing notes, saying goodbyes
6. Risk factors: Inventory of SAD PERSONS + additional
7. Protective factors: Reasons for living, children, religious beliefs, social connectedness, therapeutic alliance
8. Recent changes: Sudden calm after agitation (may indicate decision made), recent discharge, recent loss

6.4 Protective Factors

• Strong social support and connectedness
• Children in the home (especially for women)
• Religious/spiritual beliefs that discourage suicide
• Reasons for living (future-oriented thinking)
• Therapeutic alliance and engagement in treatment
• Limited access to lethal means
• Problem-solving skills
• Cultural and community belonging

6.5 Management and Prevention

Individual Level

• Safety planning (Stanley-Brown Safety Planning Intervention), NOT a "no-suicide contract"
• Warning signs
• Internal coping strategies
• Social contacts for distraction
• Family/friends to contact
• Professionals/agencies to contact
• Making the environment safe (means restriction)
• Means restriction, most effective single intervention (locking medications, removing firearms, pesticide regulation)
• Pharmacological:
• Clozapine, ONLY medication with FDA indication for suicide reduction (in schizophrenia; InterSePT trial)
• Lithium, reduces suicide risk in mood disorders (Cipriani meta-analysis)
• Ketamine/esketamine, rapid reduction in suicidal ideation (hours to days)
• Treat underlying disorder aggressively
• Psychotherapy: DBT (strongest evidence for repeated self-harm/BPD), CBT for suicide prevention (CBT-SP), CAMS (Collaborative Assessment and Management of Suicidality)
• Follow-up: Contact within 48 hours of discharge from ER/psychiatric unit; WHO SUPRE studies show brief contact interventions reduce reattempts

Population Level

• Means restriction (pesticide bans, Sri Lanka model; bridge barriers; medication packaging)
• Gatekeeper training programs (QPR, ASIST, Mental Health First Aid)
• Media guidelines (Papageno effect vs Werther effect)
• School-based programs
• Crisis helplines (iCall, Vandrevala Foundation, AASRA in India)
• Training primary care physicians in depression detection

SECTION 7: ANTIDEPRESSANTS

7.1 Classification and Mechanisms

SSRIs (Selective Serotonin Reuptake Inhibitors)

Class side effects: GI (nausea, diarrhea), sexual dysfunction (30-40%), headache, insomnia or sedation, weight gain (long-term), activation/anxiety initially, hyponatremia (SIADH, especially elderly), bleeding risk (platelet serotonin depletion)

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Class side effects: Similar to SSRIs + hypertension (NE effect), sweating, dry mouth, constipation, urinary retention

TCAs (Tricyclic Antidepressants)

Class side effects: Anticholinergic (dry mouth, constipation, urinary retention, blurred vision, cognitive impairment), cardiac (QTc prolongation, arrhythmias, lethal in overdose), sedation (H1 blockade), orthostatic hypotension (alpha-1 blockade), weight gain, seizure threshold lowering

TCA overdose: lethal due to cardiac toxicity (widened QRS, arrhythmias); management = sodium bicarbonate IV, cardiac monitoring, activated charcoal if early

MAOIs (Monoamine Oxidase Inhibitors)

Tyramine reaction ("cheese effect"): Inhibition of MAO-A in gut allows tyramine from fermented foods to enter circulation → NE release → hypertensive crisis. Avoid: aged cheese, wine, beer, fermented foods, fava beans, cured meats.

Serotonin syndrome: Combination of MAOI + serotonergic drug (SSRI, SNRI, meperidine, tramadol, dextromethorphan, St. John's wort) → hyperthermia, agitation, myoclonus, hyperreflexia, diarrhea, autonomic instability, potentially fatal. Washout period: 2 weeks for most SSRIs; 5 weeks for fluoxetine (long half-life) before starting MAOI.

Atypical/Other Antidepressants

Newer/Emerging Agents

7.2 Side Effect Profiles: Quick Reference

7.3 Serotonin Syndrome (CRITICAL EXAM TOPIC)

Triad: Mental status changes + Autonomic instability + Neuromuscular hyperactivity

Hunter Criteria (diagnostic): Must have serotonergic agent PLUS one of:

1. Spontaneous clonus
2. Inducible clonus + agitation or diaphoresis
3. Ocular clonus + agitation or diaphoresis
4. Tremor + hyperreflexia
5. Hypertonia + temperature >38C + ocular or inducible clonus

Vs Neuroleptic Malignant Syndrome (NMS):

Management:

1. Stop all serotonergic agents
2. Supportive care (IV fluids, cooling, monitoring)
3. Benzodiazepines for agitation
4. Cyproheptadine (4-8mg PO, repeat q2h, max 32mg/day), specific antidote
5. Severe: intubation, paralysis, ICU

SECTION 8: PERSISTENT MOOD DISORDERS

8.1 Persistent Depressive Disorder (Dysthymia)

DSM-5 Criteria:

• Depressed mood for most of the day, more days than not, for >= 2 years (1 year in children/adolescents)
• Plus >= 2 of: poor appetite/overeating, insomnia/hypersomnia, low energy/fatigue, low self-esteem, poor concentration/indecisiveness, hopelessness
• Never without symptoms for >2 months during the 2-year period
• No manic/hypomanic episode (→ cyclothymia or bipolar)
• "Double depression" = persistent depressive disorder + superimposed major depressive episode

Management: SSRIs/SNRIs + psychotherapy (CBT, CBASP, Cognitive Behavioral Analysis System of Psychotherapy specifically designed for chronic depression)

8.2 Cyclothymic Disorder

DSM-5 Criteria:

• >= 2 years of numerous periods of hypomanic symptoms and depressive symptoms that do NOT meet criteria for hypomanic or major depressive episode
• Never symptom-free for >2 months
• Never met criteria for a major depressive, manic, or hypomanic episode
• Significant distress or impairment

Clinical relevance:

• ~15-50% develop BP-I or BP-II over time
• Often diagnosed as "personality disorder" or "temperament"
• Treat with mood stabilizers if significant impairment; avoid antidepressant monotherapy

8.3 Disruptive Mood Dysregulation Disorder (DMDD): DSM-5

Rationale for creation: Address overdiagnosis of pediatric bipolar disorder in the USA. DMDD captures children with severe, chronic irritability who were being misclassified as bipolar.

Criteria:

• Severe recurrent temper outbursts (verbal/behavioral) grossly out of proportion
• Outbursts >= 3 times per week
• Mood between outbursts: persistently irritable or angry most of the day, nearly every day, observable by others
• Duration: >= 12 months (no period of >= 3 consecutive months without all criteria)
• Present in >= 2 of 3 settings (home, school, peers) and severe in >= 1
• Age at diagnosis: 6-18 years; age at onset: before 10 years
• Cannot coexist with ODD, intermittent explosive disorder, or bipolar disorder
• If criteria for both DMDD and ODD are met, DMDD diagnosis takes precedence

Key distinction from pediatric bipolar:

• DMDD = chronic, non-episodic irritability (the child's baseline)
• Bipolar = episodic irritability with distinct mood episodes
• DMDD prognostic trajectory → unipolar depression and anxiety in adulthood (NOT bipolar)

Management:

• Parent management training, CBT
• Stimulants (if comorbid ADHD)
• SSRIs (for irritability/depression)
• Atypical antipsychotics (risperidone, aripiprazole, for severe aggression, last resort)
• No mood stabilizer evidence

SECTION 9: RATING SCALES QUICK REFERENCE

SECTION 10: ECT IN MOOD DISORDERS

Indications in Mood Disorders

1. Severe depression with psychotic features, response rate >80%
2. Severe depression with suicidality, fastest acting treatment
3. Treatment-resistant depression, after failed adequate pharmacotherapy
4. Catatonia (including depressive catatonia)
5. Severe mania (refractory to medications, delirious mania)
6. Bipolar depression, effective, especially with psychotic features
7. Peripartum depression, when pharmacotherapy risky or ineffective
8. Nutritional compromise, patient refusing food/fluids due to depression

Key Facts for Exam

• Mechanism: Not fully understood; enhances monoaminergic transmission, promotes neuroplasticity (BDNF increase), normalizes HPA axis, anticonvulsant theory (seizure threshold increases with successive treatments)
• Electrode placement: Bilateral (bifrontotemporal) > right unilateral for efficacy; right unilateral > bilateral for cognitive side effects
• Course: Typically 6-12 sessions, 2-3 times per week
• Maintenance ECT: For relapse prevention in patients who responded to ECT; typically weekly → biweekly → monthly
• Absolute contraindication: Raised intracranial pressure (pheochromocytoma is also frequently cited)
• Side effects: Headache (most common), nausea, muscle soreness, confusion (transient), retrograde amnesia (short-term), anterograde amnesia (transient); cognitive effects less with unilateral placement
• Mortality: ~0.002% per treatment (very safe; anesthesia risk)
• Pregnancy: Safe in all trimesters; one of the safest options for severe depression in pregnancy

Cross-references: NB-06 (Schizophrenia, for overlap on antipsychotics, metabolic syndrome)

Model Answers

QUESTION 1: "Pharmacological management of Bipolar Disorders." (10 marks / 20 marks LONG ESSAY)

Model Answer (10-mark version)

Introduction (1 mark)

Bipolar disorder is a chronic relapsing condition requiring distinct pharmacological strategies for each phase: acute mania, acute bipolar depression, and maintenance/prophylaxis. Treatment goals include symptom remission, functional recovery, and relapse prevention. The pharmacological armamentarium includes mood stabilizers (lithium, valproate, carbamazepine, lamotrigine) and atypical antipsychotics.

Acute Mania Management (3 marks)

Swipe to compare →

• Discontinue antidepressants if present
• Quetiapine, olanzapine, risperidone, aripiprazole all have RCT evidence for acute mania
• Typical antipsychotics (haloperidol) still used widely but metabolic and neurological concerns
• Response assessment at 2-4 weeks; switch or combine if inadequate
• ECT for treatment-resistant mania, delirious mania, catatonic features

Bipolar Depression Management (3 marks)

This is the most challenging phase. Cardinal rule: NO antidepressant monotherapy (risk of manic switch and cycle acceleration).

If antidepressant added: ALWAYS with mood stabilizer cover; prefer SSRIs or bupropion; short course; avoid TCAs/venlafaxine.

Maintenance Treatment (2 marks)

• Continuation for minimum 2 years after acute episode; lifelong in most patients after 2+ episodes
• Lithium remains gold standard, meta-analyses confirm unique anti-suicidal effect (Cipriani et al., 2013)
• Monitor adherence, non-adherence is the leading cause of relapse

Special Populations (1 mark)

• Pregnancy: Avoid valproate (NTD, cognitive impairment in offspring). Lithium with caution (Ebstein's risk ~0.1%); use lowest effective dose; level monitoring monthly and weekly near delivery. Lamotrigine relatively safer. ECT safe.
• Elderly: Lower doses, monitor renal function closely, drug interactions
• Rapid cycling: Withdraw antidepressants, optimize mood stabilizers (valproate often preferred), check thyroid
• Children/adolescents: Lithium, aripiprazole FDA-approved; valproate and quetiapine also used

Model Answer (20-mark LONG ESSAY expansion: additional sections)

Neurobiology of Drug Action (3 marks)

• Lithium: GSK-3beta inhibition, inositol depletion (Berridge hypothesis), neuroprotection via Bcl-2, modulation of glutamate, serotonin enhancement
• Valproate: GABAergic enhancement, sodium channel blockade, HDAC inhibition (epigenetic), PKC modulation
• Carbamazepine: Sodium channel blockade, reduces glutamate release
• Lamotrigine: Sodium channel-dependent glutamate modulation; why it works in depression but not mania remains debated
• Atypical antipsychotics: D2 antagonism + 5-HT2A antagonism; quetiapine's NE reuptake inhibition (norquetiapine) may explain depression efficacy

Treatment Algorithm, Flowchart Format (2 marks)

1. Confirm diagnosis (rule out medical, substance-induced, unipolar)
2. Determine phase (mania/mixed → depression → maintenance)
3. Phase-specific treatment (as above)
4. Assess response at 2-4 weeks
5. Non-response → switch within class or add agent
6. Refractory → ECT or clozapine (mania) / esketamine or ECT (depression)

Emerging and Novel Treatments (2 marks)

• Cariprazine: D3-preferring partial agonist; evidence for bipolar depression and maintenance
• Lumateperone: Novel mechanism (5-HT2A antagonist, D2 partial agonist, SERT inhibitor); recent trials in bipolar depression
• rTMS/TMS: Limited evidence in bipolar depression
• Ketamine/esketamine: Emerging evidence for acute bipolar depression/suicidality
• Pramipexole: Dopamine agonist with some evidence for bipolar depression

Evidence Base (2 marks)

• BALANCE trial: Lithium + valproate combination superior to valproate alone for maintenance
• BOLDER trials: Quetiapine monotherapy effective for bipolar depression
• STEP-BD: Antidepressant adjunctive therapy no better than placebo for bipolar depression (controversial finding)
• InterSePT: Clozapine reduces suicidality (in schizophrenia; extrapolated to refractory bipolar)

QUESTION 2: "Course and outcome of Bipolar Affective Disorder." (10 marks)

Model Answer

Historical Context (1 mark)

Kraepelin (1921) first systematically described the longitudinal course of manic-depressive illness, noting increasing episode frequency over time, shortening of inter-episode intervals, and variable inter-episode recovery. His observations laid the groundwork for the kindling model.

Episode Characteristics (2 marks)

Longitudinal Course (3 marks)

• Kindling model (Post & Weiss): Early episodes triggered by stressors; later episodes become autonomous. Inter-episode interval shortens. This supports early intervention.
• Episode frequency: Tends to increase over time, especially without treatment. Average cycle length shortens from ~4 years (early) to <1 year (late).
• Inter-episode functioning: Only 40-50% achieve full functional recovery between episodes. Subsyndromal symptoms present in 50-60% (Judd et al., 2002, NIMH-CDS). Cognitive impairment (executive function, verbal memory) persists even in euthymia.
• Rapid cycling: Develops in 15-20% of patients, more common in women, associated with hypothyroidism and antidepressant use.
• Mixed features: Increasingly recognized as common (30-40% of episodes have some mixed features). Associated with worse outcomes.

Prognostic Factors (2 marks)

Functional and Psychosocial Outcomes (1 mark)

• 30-40% experience significant occupational disability
• Divorce rates 2-3x general population
• Reduced life expectancy by 10-15 years (cardiovascular disease, suicide)
• Suicide attempt rate 25-50%; completion rate 10-15%
• Economic burden substantial (direct + indirect costs)

Impact of Treatment on Course (1 mark)

• Lithium maintenance reduces relapse rate by 30-40%
• Treatment adherence is the strongest modifiable prognostic factor
• Psychoeducation (Colom et al.) significantly improves outcomes
• Early intervention programs show promise in reducing episode burden
• Adjunctive psychotherapy (CBT, IPSRT, FFT) improves adherence and reduces relapses

QUESTION 3: "Classify BPAD and discuss recent advances in treatment." (10 marks / 20 marks LONG ESSAY)

Model Answer (10 marks)

Classification of Bipolar Disorder (3 marks)

ICD-11 Classification:

• 6A60 Bipolar type I disorder
• 6A61 Bipolar type II disorder
• 6A62 Cyclothymic disorder

DSM-5 Classification:

• Bipolar I Disorder (at least one manic episode)
• Bipolar II Disorder (at least one hypomanic + one major depressive episode)
• Cyclothymic Disorder (chronic fluctuating mood, sub-threshold)
• Substance/Medication-Induced Bipolar
• Bipolar Due to Another Medical Condition
• Other Specified / Unspecified Bipolar

DSM-5 Specifiers: With anxious distress, with mixed features, with rapid cycling, with melancholic features, with atypical features, with mood-congruent/incongruent psychotic features, with catatonia, with peripartum onset, with seasonal pattern.

Key DSM-5 change from DSM-IV: "Mixed episode" replaced by "with mixed features" specifier applicable to any episode.

Recent Advances in Pharmacotherapy (4 marks)

Advances in Neuromodulation (1 mark)

• rTMS: Growing evidence for bipolar depression (left DLPFC stimulation)
• Theta-burst stimulation (TBS): Accelerated protocols (Stanford SAINT protocol, 5 days vs 4-6 weeks)
• DBS: Experimental targets (subcallosal cingulate, ventral capsule/ventral striatum)
• ECT remains most effective physical treatment; ultrabrief pulse reduces cognitive effects

Advances in Psychotherapy (1 mark)

• Family-Focused Therapy (FFT, Miklowitz): Reduces relapse in early-course bipolar
• IPSRT (Frank): Social rhythm stabilization reduces recurrence
• CBT for bipolar (Lam et al.): Reduces depressive relapses
• Psychoeducation (Colom & Vieta): Group psychoeducation is evidence-based for relapse prevention
• Digital interventions: Smartphone-based mood monitoring (MONARCA, SIMPLe)

Advances in Understanding and Biomarkers (1 mark)

• Staging models (Berk, Kapczinski): Stage 0-4 progression; early intervention focus
• Neuroimaging biomarkers: Amygdala hyperactivity, PFC hypoactivity; potential for treatment response prediction
• Polygenic risk scores: Improving but not yet clinical utility
• Circadian rhythm interventions: Dark therapy, blue-light blocking for acute mania
• Inflammatory markers: CRP, IL-6 as potential predictors of treatment response
• Metabolomics/proteomics: Emerging signatures for bipolar subtypes

QUESTION 4: "Genetics of Bipolar disorders." (10 marks)

Model Answer

Heritability (2 marks)

Bipolar disorder is one of the most heritable psychiatric conditions, with estimated heritability of approximately 85% from twin studies. This is higher than most other psychiatric disorders (schizophrenia ~80%, MDD ~40%, anxiety disorders ~30-40%).

Family Studies (1 mark)

• First-degree relatives have 5-10x risk of developing BPAD compared to general population
• Risk of any mood disorder in first-degree relatives: ~25%
• First-degree relatives also at increased risk for unipolar depression, schizoaffective disorder
• The closer the genetic relationship, the higher the concordance

Twin Studies (1 mark)

• Monozygotic concordance: 40-70% (varies by study)
• Dizygotic concordance: 5-10%
• MZ concordance <100% confirms environmental factors play a role despite high heritability
• The gap between MZ and DZ concordance provides the strongest evidence for genetic contribution

Adoption Studies (1 mark)

• Biological relatives of bipolar adoptees have higher rates of mood disorders than adoptive relatives
• Mendlewicz & Rainer (1977): foundational adoption study showing genetic transmission
• Environmental contribution exists but is smaller than genetic contribution

Molecular Genetics (3 marks)

Genome-Wide Association Studies (GWAS):

• Bipolar Disorder Working Group of PGC: identified 64+ genome-wide significant loci (latest meta-analysis)
• Polygenic architecture: hundreds of common variants, each with small effect (OR 1.05-1.15)

Key genes and pathways:

Rare variants: Copy number variants (CNVs), duplications at 16p11.2, deletions at 3q29, 15q11.2, overlap with schizophrenia and ASD.

Genetic Overlap with Other Disorders (1 mark)

• Bipolar shares more genetic variance with schizophrenia than with unipolar depression
• Cross-Disorder Group of PGC: identified shared loci across BPAD, schizophrenia, MDD, ADHD, ASD
• Genetic correlation: BPAD-SCZ ~0.68, BPAD-MDD ~0.44
• Supports dimensional/spectrum models rather than strict categorical boundaries
• Schizoaffective disorder may represent genetic intermediate

Clinical Implications (1 mark)

• Genetic counseling: Empirical risk figures for families (10-15% risk for offspring of one affected parent; 50-70% if both parents affected)
• Pharmacogenomics: HLA-B*1502 screening before carbamazepine; CYP2D6/CYP2C19 for antidepressant metabolism
• Polygenic risk scores: Not yet clinical utility but improving; may predict illness course, treatment response
• Gene-environment interaction: Childhood adversity + genetic vulnerability = highest risk
• Ethical considerations: Genetic testing, discrimination, insurance implications

QUESTION 5: "Persistent mood disorders." (10 marks)

Model Answer

Classification (2 marks)

Persistent (chronic) mood disorders are characterized by prolonged, sub-threshold mood disturbance. DSM-5 includes:

1. Persistent Depressive Disorder (PDD), replaces DSM-IV dysthymic disorder; also incorporates chronic major depression
2. Cyclothymic Disorder, chronic fluctuation between sub-threshold hypomania and depression
3. Disruptive Mood Dysregulation Disorder (DMDD), DSM-5 addition; children with chronic severe irritability

ICD-11: Dysthymic disorder (6A72), Cyclothymic disorder (6A62)

Persistent Depressive Disorder / Dysthymia (3 marks)

Criteria: Depressed mood more days than not for >= 2 years (1 year in children/adolescents), plus >= 2 of: appetite changes, sleep changes, low energy, low self-esteem, poor concentration, hopelessness. Never symptom-free for >2 months.

DSM-5 specifiers: With anxious distress, with mixed features, with melancholic features, with atypical features, with mood-congruent/incongruent psychotic features, in partial/full remission, early/late onset, with pure dysthymic syndrome vs with persistent major depressive episode vs with intermittent major depressive episodes.

Epidemiology: Lifetime prevalence 3-6%; F:M = 2:1; onset often insidious in adolescence or early adulthood.

Double depression: PDD + superimposed major depressive episode. Present in ~75% of PDD patients. Worse prognosis than MDE alone, higher relapse rates, poorer treatment response.

Management:

• SSRIs/SNRIs first-line (similar efficacy to MDE treatment)
• Psychotherapy: CBT, CBASP (McCullough, Cognitive Behavioral Analysis System of Psychotherapy, specifically designed for chronic depression), IPT
• Combined pharmacotherapy + psychotherapy superior to either alone (Keller et al., 2000, nefazodone + CBASP study)
• Duration of treatment: prolonged; high relapse risk on discontinuation

Cyclothymic Disorder (3 marks)

Criteria: >= 2 years (1 year in adolescents) of numerous periods with hypomanic symptoms and depressive symptoms not meeting full criteria for hypomanic or major depressive episode. Never symptom-free for >2 months. No full manic, hypomanic, or major depressive episode during initial 2-year period.

Epidemiology: Lifetime prevalence 0.4-1%; equal sex distribution; onset usually adolescence/early adulthood.

Course: 15-50% progress to BP-I or BP-II. Chronic and fluctuating. Often misdiagnosed as personality disorder (especially borderline, the affective instability overlap).

Relationship to bipolar: Considered part of the bipolar spectrum. Family studies show increased bipolar disorder in relatives. Temperament theories (Akiskal) place cyclothymia on a continuum with bipolar.

Management:

• Mood stabilizers (lithium, valproate) if significant functional impairment
• Avoid antidepressant monotherapy (risk of destabilization/switch)
• Psychoeducation about mood patterns
• Social rhythm stabilization
• Psychotherapy supportive but limited evidence

Disruptive Mood Dysregulation Disorder, DMDD (2 marks)

Rationale: Created in DSM-5 to address the overdiagnosis of pediatric bipolar disorder. Captures children with severe chronic irritability who were being misclassified.

Criteria: Severe recurrent temper outbursts >= 3x/week; persistently irritable/angry mood between outbursts (most of day, nearly every day); present >= 12 months (no >= 3-month symptom-free period); in >= 2/3 settings; age 6-18 years, onset before 10 years.

Key distinction: DMDD = chronic non-episodic irritability (baseline state) vs pediatric bipolar = episodic mood changes with discrete episodes.

Prognostic trajectory: Develops into unipolar depression and anxiety disorders in adulthood, NOT bipolar disorder. This distinguishes it fundamentally from true pediatric bipolar.

Management: Parent management training, CBT; stimulants if comorbid ADHD; SSRIs for depression/anxiety component; atypical antipsychotics for severe aggression as last resort.

QUESTION 6: "Recent advances in management of mood disorders." (10 marks)

Model Answer

Pharmacological Advances (4 marks)

Bipolar disorder:

• Cariprazine: D3-preferring partial agonist; first drug showing superiority for both bipolar mania and depression with maintenance approval
• Lumateperone: Novel multimodal mechanism; adjunctive for bipolar depression
• Lurasidone: Established for bipolar depression; favorable metabolic profile
• Long-acting injectable antipsychotics: Aripiprazole LAI for bipolar maintenance, addresses adherence
• Valproate restrictions: EMA/MHRA guidelines restricting use in women of childbearing age

Unipolar depression:

• Esketamine (Spravato): Intranasal NMDA antagonist; FDA approved for TRD (2019) and MDD with suicidal ideation (2020); rapid onset within hours
• Brexanolone (Zulresso): IV allopregnanolone; FDA approved for postpartum depression (2019); GABA-A modulation
• Zuranolone (Zurzuvae): Oral neuroactive steroid; FDA approved for PPD (2023); 14-day course
• Dextromethorphan/bupropion (Auvelity): Glutamate modulation; FDA approved for MDD (2022); faster onset than traditional antidepressants
• Psilocybin: Breakthrough therapy designation for TRD; phase II/III trials showing sustained response after 1-2 sessions with psychotherapy support

Neuromodulation Advances (2 marks)

• Accelerated TMS protocols: Stanford SAINT protocol, 10 sessions/day for 5 days; rapid response in TRD (remission rates ~80% in initial trials)
• Theta-burst stimulation (TBS): Equivalent efficacy to standard rTMS in shorter session time
• MST (Magnetic Seizure Therapy): Aims to produce ECT-like efficacy with fewer cognitive effects; under investigation
• tDCS (Transcranial Direct Current Stimulation): Modest evidence for depression; home-based protocols being tested
• Focused ultrasound: Experimental; non-invasive deep brain stimulation

Psychotherapy Advances (1 mark)

• Internet-delivered CBT (iCBT): Non-inferior to face-to-face for mild-moderate depression; scalable
• Behavioral activation: Standalone treatment non-inferior to CBT for depression (COBRA trial)
• CBASP: Specifically designed for chronic depression; superior to antidepressant alone when combined
• Digital phenotyping: Smartphone sensors detecting mood episodes in bipolar (passive monitoring)

Precision Medicine and Biomarkers (1 mark)

• Pharmacogenomics: CYP2D6/CYP2C19 testing for antidepressant selection (GeneSight, etc.)
• Inflammatory biomarkers: CRP-guided treatment selection, high CRP may predict better response to anti-inflammatory or duloxetine
• Staging models: Berk staging for bipolar; early intervention paradigm
• Machine learning: Predicting treatment response from clinical + neuroimaging data

Guideline Updates (1 mark)

• CANMAT 2018: Updated bipolar treatment guidelines; lurasidone and cariprazine incorporated
• NICE 2023 update: Valproate restrictions formalized
• APA Practice Guidelines: Updated depression management incorporating esketamine
• WHO mhGAP: Simplified algorithms for non-specialist settings (relevant to Indian context)

Emerging Paradigms (1 mark)

• Chronotherapy: Combined sleep deprivation + light therapy + sleep phase advance, rapid antidepressant effect
• Anti-inflammatory approaches: Celecoxib, minocycline augmentation trials positive
• Gut-brain axis: Probiotics ("psychobiotics") as adjunctive treatment, early evidence
• Ketamine clinics: Growing off-label IV ketamine use for TRD worldwide

QUESTION 7: "Disruptive Mood Dysregulation Disorder." (10 marks)

Model Answer

Background and Rationale (2 marks)

DMDD was introduced in DSM-5 (2013) to address the dramatic increase in pediatric bipolar disorder diagnoses in the United States (a 40-fold increase between 1994-2003). Leibenluft et al. at NIMH identified that many children diagnosed with bipolar actually had severe chronic irritability (termed "Severe Mood Dysregulation" in research) rather than episodic mood disturbance. Follow-up studies showed these children developed unipolar depression and anxiety in adulthood, NOT bipolar disorder, confirming they were a distinct clinical entity.

Diagnostic Criteria (3 marks)

1. Severe recurrent temper outbursts manifested verbally (rage) and/or behaviorally (physical aggression) grossly out of proportion in intensity or duration to the situation
2. Temper outbursts inconsistent with developmental level
3. Outbursts occur >= 3 times per week on average
4. Mood between outbursts is persistently irritable or angry most of the day, nearly every day, and observable by others (parents, teachers, peers)
5. Criteria present for >= 12 months; no period of >= 3 consecutive months without all symptoms
6. Present in >= 2 of 3 settings (home, school, peers) and severe in at least one
7. Age 6-18 years at diagnosis; onset of symptoms before age 10 years
8. Never a distinct period lasting >1 day meeting full criteria for manic/hypomanic episode
9. Not better explained by another mental disorder; does not coexist with ODD, intermittent explosive disorder, or bipolar disorder

Differential Diagnosis (2 marks)

Course and Prognosis (1 mark)

• Prevalence: 2-5% of children (community studies)
• Develops into unipolar depression and anxiety disorders in adulthood (NOT bipolar, this is the critical distinction)
• High comorbidity with ADHD, ODD (when diagnosed separately), anxiety disorders
• Associated with significant academic and social impairment
• Suicide risk elevated compared to non-DMDD peers

Management (2 marks)

Psychosocial (first-line):

• Parent management training (structured behavioral interventions)
• CBT (anger management, emotion regulation skills)
• School-based interventions

Pharmacological:

• Stimulants: If comorbid ADHD (common); methylphenidate may improve irritability and outbursts
• SSRIs: For underlying depressive/anxious component
• Atypical antipsychotics: Risperidone, aripiprazole for severe aggression/irritability, should be last resort due to metabolic effects in children
• NO mood stabilizer evidence for DMDD (unlike bipolar)

QUESTION 8: "Define TRD. Discuss staging and management." (10 marks / 20 marks LONG ESSAY)

Model Answer

Definition (2 marks)

Treatment-Resistant Depression (TRD) is defined as failure to achieve adequate clinical response (typically <50% improvement in depression rating scale scores) after at least 2 adequate antidepressant trials from different pharmacological classes, each at adequate dose for adequate duration (minimum 6-8 weeks at therapeutic dose with confirmed adherence).

Pseudo-resistance (must exclude before diagnosing TRD):

• Inadequate dose or duration of current trial
• Non-adherence (common, up to 50% of patients)
• Misdiagnosis: bipolar depression, medical causes (hypothyroidism, anemia, B12 deficiency, Cushing's, cerebral lesion), substance use, personality disorder
• Untreated comorbidities: anxiety disorders, substance use, chronic pain, sleep disorders

Staging Models (3 marks)

Thase-Rush Model (most commonly cited):

Massachusetts General Hospital (MGH) Staging Method:

• Quantitative scoring system: 1 point per failed adequate trial, 0.5 points for optimization, 0.5 for augmentation, 3 points for ECT failure
• Total score represents overall treatment resistance burden
• More granular and better suited for research

European Staging Model (Souery):

• Considers number of failed adequate trials and augmentation strategies
• Integrates chronicity as a factor

Management Algorithm (4 marks)

Step 1, Optimization (confirm adequacy):

• Maximize dose to highest tolerated
• Ensure >= 8 weeks at therapeutic dose
• Verify adherence (serum levels if available, e.g., TCA levels)
• Address comorbidities (anxiety, substance use, sleep, medical)
• Psychotherapy if not already engaged

Step 2, Switching:

• Indicated when NO response to current agent
• Within class: escitalopram → sertraline (limited evidence for benefit)
• Between classes: SSRI → SNRI → bupropion → TCA → MAOI
• Allow adequate washout for MAOI (2 weeks from most drugs; 5 weeks from fluoxetine)

Step 3, Augmentation:

• Indicated when PARTIAL response (some improvement but inadequate)
• Lithium augmentation: Most evidence-based; 0.6-0.8 mEq/L; response in 2-4 weeks; Bauer et al. meta-analysis confirms efficacy
• Atypical antipsychotic augmentation: Aripiprazole (2-5mg), quetiapine (50-300mg), olanzapine (2.5-10mg), brexpiprazole (1-3mg), all FDA-approved for augmentation
• Thyroid augmentation: T3 (liothyronine) 25-50 mcg/day; even in euthyroid patients; accelerates and augments response

Step 4, Combination antidepressants:

• SSRI/SNRI + mirtazapine ("California rocket fuel" = venlafaxine + mirtazapine)
• SSRI + bupropion (complementary mechanisms, may reduce sexual side effects)
• NEVER combine SSRI + MAOI or SNRI + MAOI

Step 5, Esketamine:

• Intranasal (Spravato); FDA approved 2019
• Used WITH concurrent oral antidepressant
• REMS program: administer in certified setting, monitor 2 hours
• Rapid onset (hours to days); dosing: 56mg or 84mg twice weekly initially → weekly → biweekly
• Side effects: dissociation, dizziness, sedation, nausea, increased BP

Step 6, ECT:

• Gold standard for severe/refractory depression
• 70-90% response rate in TRD
• Bilateral > right unilateral for efficacy
• Especially indicated: psychotic features, severe suicidality, catatonia, nutritional compromise
• Maintenance ECT for sustained benefit

Step 7, Experimental/emerging:

• rTMS (left DLPFC high-frequency or right DLPFC low-frequency)
• VNS (implanted; FDA approved for chronic TRD unresponsive to >= 4 treatments)
• DBS (investigational; subcallosal cingulate)
• Psilocybin-assisted therapy (phase II/III)
• IV ketamine (off-label)

Emerging Treatments (1 mark)

• Accelerated TMS (SAINT protocol): 5-day course; promising open-label and RCT data
• Psilocybin: Phase II data showing sustained antidepressant effects after 1-2 sessions
• MDMA-assisted therapy: Primarily PTSD; some MDD overlap data
• Anti-inflammatory augmentation: Celecoxib, minocycline in clinical trials
• Zuranolone: Oral neuroactive steroid; approved for PPD, trials in MDD ongoing

QUESTION 9: "Depression in the elderly: clinical features, differential diagnosis, management." (10 marks)

Model Answer

Epidemiology and Context (1 mark)

Depression affects 10-15% of community-dwelling elderly and up to 40% of those in institutional care. Late-onset depression (onset >60 years) may represent a distinct clinical entity linked to cerebrovascular disease (vascular depression hypothesis, Alexopoulos, 1997). Depression in elderly is underdiagnosed and undertreated due to diagnostic complexity and attribution of symptoms to "normal aging."

Clinical Features (3 marks)

Differences from younger adults:

Vascular depression features:

• Late onset (no prior psychiatric history)
• Executive dysfunction out of proportion
• Psychomotor retardation
• Apathy > sadness
• White matter hyperintensities on MRI
• Associated vascular risk factors (HTN, DM, smoking)
• Poorer response to antidepressants
• Greater disability

Differential Diagnosis (3 marks)

Pseudodementia vs dementia, key distinguishing features:

• Pseudodementia: rapid onset, "don't know" answers, inconsistent memory, psychiatric history, responds to antidepressants
• Dementia: insidious onset, near-miss answers/confabulates, progressive, temporal gradient memory loss, does not respond to antidepressants
• CRITICAL: pseudodementia patients have 30-50% risk of developing true dementia within 5 years

Management (3 marks)

Pharmacological:

• "Start low, go slow, but go", aim for therapeutic doses
• SSRIs preferred: Escitalopram, sertraline (fewest drug interactions)
• Mirtazapine: Good choice if insomnia, poor appetite, weight loss (sedating, appetite-stimulating)
• Duloxetine: Useful if comorbid neuropathic pain
• Venlafaxine: Effective but monitor BP
• Avoid TCAs: Anticholinergic effects (confusion, falls, urinary retention, constipation, cardiac); orthostatic hypotension
• Avoid benzodiazepines: Falls, confusion, paradoxical disinhibition, dependence
• Monitor for hyponatremia: SSRIs/SNRIs cause SIADH; higher risk in elderly; check sodium at 1-2 weeks
• ECT: Safe and highly effective in elderly; may be first-line for severe depression with psychotic features, suicidality, or inability to tolerate medications

Psychotherapy:

• CBT adapted for elderly (slower pace, written materials, involve family)
• Problem-solving therapy
• Interpersonal therapy (IPT)
• Behavioral activation
• Reminiscence therapy (group or individual)

Other considerations:

• Address social isolation, bereavement, loss of role
• Treat comorbid medical conditions
• Optimize sensory function (hearing aids, glasses)
• Exercise (moderate evidence for depression improvement)
• Suicide risk: higher in elderly men; always assess access to means; lethal methods more common in elderly

QUESTION 10: "Suicide: risk factors, assessment scales, prevention strategies." (10 marks)

Model Answer

Epidemiology (1 mark)

Globally: ~800,000 deaths by suicide annually (WHO). India: ~12/100,000 population (NCRB 2021), accounting for ~36% of global female suicides and ~24% of male suicides. Peak age: 18-30 years (younger than Western countries). Suicide decriminalized in India under Mental Healthcare Act 2017, Section 115, attempted suicide presumed to be under severe stress.

Risk Factors (3 marks)

SAD PERSONS mnemonic:

• Sex: Male (completed); Female (attempted)
• Age: >65 years and 15-30 years
• Depression/psychiatric illness
• Previous attempt (STRONGEST single predictor)
• Ethanol/substance abuse
• Rational thinking loss (psychosis)
• Social supports lacking
• Organized plan with intent
• No spouse (single/divorced/widowed)
• Sickness (chronic illness, chronic pain)

Additional risk factors:

• Family history of suicide
• Access to lethal means (firearms, pesticides)
• Recent psychiatric discharge (first 1-4 weeks highest risk)
• Hopelessness (Beck Hopelessness Scale, more predictive than depression severity alone)
• Impulsivity/aggression traits
• History of childhood abuse/neglect
• LGBTQ+ identity (especially youth)
• Media contagion (Werther effect)

Indian-specific:

• Farming suicides (debt, crop failure, drought, NCRB reports)
• Student suicides (academic pressure, competitive exam failure)
• Dowry-related deaths
• Common methods: hanging, poisoning (organophosphates, rural), self-immolation

Assessment Scales (3 marks)

Clinical assessment framework (beyond scales):

1. Ideation: passive vs active
2. Plan: specific method, timeframe
3. Means: access to intended method
4. Intent: strength of desire, reasons for living
5. Preparedness: giving possessions, writing notes
6. Protective factors: children, religion, social support
7. Recent changes: sudden calm, recent discharge, recent loss

Prevention Strategies (3 marks)

Universal (population-level):

• Means restriction: Most effective single intervention, pesticide bans (Sri Lanka model reduced suicides by 50%), bridge barriers (Golden Gate Bridge), medication blister packs, firearm storage laws
• Media guidelines: WHO recommendations; Papageno effect (responsible reporting reduces imitation) vs Werther effect (sensationalized reporting increases imitation)
• School-based programs: Signs of Suicide (SOS), Yellow Ribbon
• Gatekeeper training: QPR (Question, Persuade, Refer), ASIST, Mental Health First Aid, training non-mental health professionals to identify and refer
• Crisis helplines: iCall, Vandrevala Foundation, AASRA (India)

Selective (targeted to high-risk groups):

• Screening in primary care (PHQ-9, EPDS for peripartum)
• Training primary care physicians in depression detection and management
• Follow-up contact after suicide attempt (WHO BIC study, brief intervention and contact)
• Military/police/medical professional targeted programs

Indicated (individual-level):

• Safety planning (Stanley-Brown model, NOT "no-suicide contracts" which are ineffective)
• Pharmacotherapy: Clozapine (FDA-approved for suicide reduction in schizophrenia, InterSePT trial), Lithium (reduces suicide in mood disorders, Cipriani meta-analysis), Ketamine/esketamine (rapid reduction in suicidal ideation)
• Psychotherapy: DBT (gold standard for repeated self-harm/BPD), CBT-SP (CBT for Suicide Prevention), CAMS (Collaborative Assessment and Management of Suicidality)
• Post-discharge follow-up: Contact within 48 hours; bridging appointments; intensive outpatient

QUESTION 11: "Newer antidepressants: classification and clinical applications." (10 marks)

Model Answer

Introduction (1 mark)

"Newer antidepressants" encompasses agents developed beyond the traditional SSRI/SNRI/TCA/MAOI framework, with novel mechanisms of action. These include multimodal serotonergic agents, glutamate modulators, neurosteroids, and psychedelic-assisted therapies.

Classification by Mechanism (4 marks)

Clinical Applications (3 marks)

Vortioxetine:

• Unique pro-cognitive effects, improves processing speed, executive function, attention in MDD
• Useful when cognitive symptoms are prominent
• Better sexual dysfunction profile than SSRIs
• Dose-related GI side effects (nausea)
• 5-20mg/day

Agomelatine:

• Resynchronizes circadian rhythm (MT1/MT2 agonism)
• No sexual dysfunction, no weight gain, no discontinuation syndrome
• Monitor LFTs (hepatotoxicity risk, check at baseline, 3, 6, 12, 24 weeks)
• Useful for depression with sleep-wake cycle disruption
• Not available in USA; available in India
• 25-50mg at bedtime

Esketamine:

• Rapid onset (hours); glutamate-mediated neuroplasticity
• For TRD (with concurrent oral antidepressant) and MDD with acute suicidal ideation
• Nasal spray; REMS program, administer in clinic, monitor 2 hours
• Side effects: dissociation, dizziness, sedation, nausea, BP elevation
• Dosing: 56mg or 84mg; twice weekly (wk 1-4) → weekly (wk 5-8) → weekly or biweekly

Brexanolone:

• First drug specifically approved for postpartum depression
• IV infusion over 60 hours; inpatient setting
• Rapid response (within 24-48 hours)
• Very expensive; limited availability
• REMS: sedation monitoring, pulse oximetry

Zuranolone:

• First ORAL medication for postpartum depression
• 14-day course (50mg nightly)
• Rapidly effective
• Can be taken at home (unlike brexanolone)

Bupropion/dextromethorphan:

• Glutamate mechanism + monoaminergic effects
• Faster onset than traditional antidepressants (1 week in trials)
• For MDD (not specifically TRD)

Evidence Summary and Clinical Decision-Making (2 marks)

• Cognitive symptoms dominant → vortioxetine
• Circadian disruption/sleep issues → agomelatine
• Treatment-resistant → esketamine (with oral antidepressant)
• Postpartum depression → brexanolone (severe, inpatient) or zuranolone (oral)
• Rapid onset needed → esketamine or bupropion/dextromethorphan
• Bipolar depression → cariprazine, lurasidone
• These agents expand the toolkit but do NOT replace first-line SSRIs/SNRIs for initial treatment of MDD

QUESTION 12: "Lithium: mechanism of action, monitoring, side effects, toxicity and management." (10 marks)

Model Answer

Mechanism of Action (3 marks)

Monitoring Schedule (2 marks)

Therapeutic ranges:

• Acute mania: 0.8-1.2 mEq/L
• Maintenance: 0.6-1.0 mEq/L
• Elderly: 0.4-0.8 mEq/L (more sensitive)
• Toxicity concern: >1.5 mEq/L

Side Effects (2 marks)

Toxicity and Management (3 marks)

Clinical features by severity:

Common precipitants:

• Dehydration (fever, diarrhea, vomiting, reduced intake, hot weather)
• NSAIDs (ibuprofen, naproxen, reduce renal lithium clearance)
• ACE inhibitors/ARBs (reduce GFR)
• Thiazide diuretics (increase lithium reabsorption in proximal tubule)
• Sodium restriction/depletion
• Acute renal impairment from any cause

Management:

1. Stop lithium immediately
2. IV normal saline 0.9%, aggressive rehydration to restore volume and sodium; enhances renal lithium excretion
3. Serial lithium levels every 2-4 hours until consistently declining
4. Monitor: renal function, electrolytes, ECG, neurological status
5. Correct precipitating cause (stop offending drugs, treat infection/dehydration)
6. Avoid further nephrotoxins
7. Hemodialysis, indications:
8. Serum lithium >4.0 mEq/L (regardless of symptoms)
9. Serum lithium >2.5 mEq/L with severe symptoms
10. Renal failure (impaired excretion)
11. Deterioration despite supportive care
12. Post-dialysis: monitor for rebound (lithium redistributes from tissue compartments; may need repeat dialysis)
13. Whole bowel irrigation if recent ingestion of sustained-release formulation (activated charcoal does NOT bind lithium)
14. Benzodiazepines for seizures
15. ICU admission for severe toxicity

QUESTION 13: "Describe negative symptoms in schizophrenia and discuss management." (10 marks)

Brief note for mood disorder context:

Negative symptoms (avolition, anhedonia, flat affect, alogia, asociality) overlap significantly with depressive features. In schizoaffective disorder, distinguishing "primary" negative symptoms from depressive episodes is critical for treatment planning. If depression is contributing: treat depression aggressively (antidepressants with mood stabilizer cover). If primary negative symptoms: cariprazine (D3 partial agonism), amisulpride (low dose), consider psychosocial interventions.

QUESTION 14: "What is metabolic syndrome and its relationship with psychotropic medications?" (10 marks)

Model Answer

Definition and Criteria (2 marks)

Metabolic syndrome is a cluster of interconnected metabolic abnormalities that increase cardiovascular disease and type 2 diabetes risk. Defined by NCEP ATP-III criteria (3 of 5):

Prevalence in psychiatric populations: 2-3x general population (30-50% in schizophrenia/bipolar).

Pathophysiology (1 mark)

• Central insulin resistance
• Visceral adiposity → inflammation → endothelial dysfunction
• Psychotropic medications compound inherent metabolic vulnerability
• Shared genetic/environmental risk factors between severe mental illness and metabolic disease
• Sedentary lifestyle, poor diet, smoking more common in psychiatric patients
• Illness-intrinsic factors (HPA axis dysregulation, inflammation)

Psychotropic Medications and Metabolic Risk (4 marks)

Mood stabilizers:

• Valproate: Significant weight gain, insulin resistance, PCOS
• Lithium: Moderate weight gain, hypothyroidism
• Carbamazepine: Mild weight gain
• Lamotrigine: Weight-neutral

Antidepressants:

• Mirtazapine: Weight gain (H1 blockade)
• TCAs (amitriptyline): Weight gain
• Paroxetine: Weight gain (most among SSRIs)
• SSRIs: Generally mild or weight-neutral short-term; some long-term gain
• Bupropion: Weight-neutral to mild loss

Monitoring (2 marks)

Per ADA/APA consensus guidelines (2004, updated):

Management (1 mark)

• Lifestyle intervention first: diet, exercise, smoking cessation
• Switch to lower metabolic risk medication if clinically feasible (e.g., olanzapine → aripiprazole)
• Metformin: Best-studied pharmacological intervention for antipsychotic-associated weight gain (500-2000mg/day)
• Topiramate: Adjunctive for weight reduction
• GLP-1 receptor agonists (liraglutide, semaglutide): Emerging evidence in psychiatric populations
• Treat individual components: statins for dyslipidemia, antihypertensives, glucose management
• Regular cardiovascular risk assessment

QUESTION 15: "Discuss the role of ECT in treatment of mood disorders." (10 marks)

Model Answer

Indications in Mood Disorders (3 marks)

Depression:

1. Severe depression with psychotic features, response rate >80% (superior to pharmacotherapy alone)
2. Severe depression with acute suicidality, fastest acting antidepressant treatment
3. Treatment-resistant depression (Thase-Rush Stage V)
4. Catatonic depression
5. Depression with nutritional compromise (refusing food/fluids)
6. Depression in pregnancy, when pharmacotherapy is ineffective or poses unacceptable risk
7. Depression in elderly, safe, effective, sometimes preferred over polypharmacy

Bipolar disorder:

1. Acute mania (refractory to medications, delirious mania, catatonic features)
2. Bipolar depression (severe, psychotic, or refractory)
3. Mixed states with severe features
4. Rapid cycling (as adjunct to mood stabilizers)

Mechanism (1 mark)

The precise mechanism remains incompletely understood. Leading theories:

• Monoamine enhancement: Increases 5-HT, NE, DA neurotransmission
• Neuroplasticity: Increases BDNF, promotes hippocampal neurogenesis
• HPA axis normalization: Reduces cortisol hypersecretion
• Anticonvulsant theory: Progressive increase in seizure threshold across sessions reflects GABAergic enhancement
• Neuroinflammatory modulation: Reduces pro-inflammatory cytokines
• Connectivity changes: Normalizes default mode network hyperconnectivity in depression

Procedure Key Points (2 marks)

• Pre-ECT workup: Physical exam, blood tests (FBC, electrolytes, blood sugar), ECG (>40 yrs), chest X-ray (if indicated), anesthesia assessment, informed consent, dental assessment
• Electrode placement: Bilateral (bifrontotemporal) vs right unilateral, bilateral more effective but more cognitive side effects; ultra-brief pulse right unilateral optimizes the balance
• Anesthesia: Short-acting agents, thiopental/propofol (induction) + succinylcholine (muscle relaxation) + atropine/glycopyrrolate (to reduce secretions)
• Seizure adequacy: Motor seizure >= 20 seconds (15 seconds by EEG); subthreshold → re-stimulate with higher charge
• Course: 6-12 sessions; 2-3 times per week; depression typically responds by 6-8 sessions
• Stimulus parameters: Charge (millicoulombs), pulse width (brief 0.5-2ms vs ultrabrief 0.25-0.3ms), frequency (Hz), current (mA), duration
• Maintenance ECT: For relapse prevention; typically weekly → biweekly → monthly; indicated when pharmacotherapy alone insufficient to prevent relapse

Evidence Base (2 marks)

• UK ECT Review Group (2003): ECT superior to sham ECT and pharmacotherapy for depression
• CORE study: Bilateral ECT + nortriptyline superior to either alone for psychotic depression
• Kellner et al. (2006): ECT + nortriptyline + lithium maintenance reduces relapse after successful ECT
• Efficacy rates: 70-90% for severe depression; 80%+ for psychotic depression; 50-60% for TRD
• Speed of response: Faster than any pharmacological intervention, significant improvement often within 1-2 weeks
• Mania: Limited RCT data but clinical experience supports efficacy; particularly for delirious mania and treatment-resistant mania
• Comparison with pharmacotherapy: ECT superior to pharmacotherapy for severe depression, psychotic depression, and acutely suicidal patients; generally reserved as later-line due to logistics and stigma

Side Effects (1 mark)

• Most common: Headache (most frequent), nausea, muscle soreness (from succinylcholine)
• Cognitive: Transient confusion (minutes to hours post-treatment), anterograde amnesia (usually resolves weeks after course), retrograde amnesia (for events around treatment period; usually resolves, but some patients report persistent autobiographical memory gaps)
• Cardiovascular: Transient bradycardia (vagal stimulation during seizure) followed by tachycardia; usually benign
• Cognitive effects less with: Right unilateral > bilateral, ultrabrief > brief pulse, lower stimulus intensity
• Mortality: ~0.002% per treatment (comparable to general anesthesia risk)
• Absolute contraindication: Raised intracranial pressure (risk of herniation); pheochromocytoma (hypertensive crisis)
• Relative contraindications: Recent cerebral hemorrhage, unstable aneurysm, recent MI, retinal detachment

Special Populations (1 mark)

• Elderly: Safe and effective; may be preferred over polypharmacy; post-ECT delirium risk higher
• Pregnancy: Safe in all trimesters; one of the safest treatments for severe depression in pregnancy; monitor fetal heart, avoid aortocaval compression (left lateral tilt), obstetric standby in third trimester
• Adolescents: Used in treatment-resistant cases; similar efficacy to adults; parental consent required
• Medical comorbidity: Generally safe with appropriate anesthetic management; cardiac patients need cardiology clearance

Mnemonics & Memory Tricks

MNEMONIC 1: DIGFAST: Symptoms of Mania

DIGFAST

Swipe to compare →

MNEMONIC 2: SIG E CAPS: Depression (DSM-5 Criteria)

SIG E CAPS

Plus depressed mood (most of day, nearly every day)

MNEMONIC 3: Bipolar I vs II vs Cyclothymia: "The 1-2-C Rule"

The 1-2-C Rule

Bipolar I = 1 manic episode is enough (depression not required for diagnosis)

• Mania >= 7 days OR hospitalization
• Psychotic features CAN occur
• Marked functional impairment

Bipolar II = 2 types needed (hypomania + depression BOTH required)

• Hypomania >= 4 days
• NEVER a full manic episode
• If psychosis occurs, it's BP-I by definition

Cyclothymia = Chronic but sub-threshold (never meets full criteria for either pole)

• >= 2 years of fluctuation
• Sub-threshold hypomania + sub-threshold depression
• Never symptom-free for >2 months

Memory trick: "One episode of mania = BP-I, Two poles required = BP-II, Chronically cycling below threshold = Cyclothymia"

MNEMONIC 4: Lithium Side Effects: "LITHIUM"

LITHIUM

MNEMONIC 5: Lithium Monitoring: "RENAL ThyCa" (Renal, Thyroid, Calcium)

RENAL ThyCa

Baseline before starting lithium:

• Renal function (creatinine, eGFR)
• ECG (if >40 or cardiac history)
• Nutrition/weight (BMI)
• And electrolytes
• Lithium level (then 5-7 days after starting)
• Thyroid (TSH, free T4)
• Calcium (+ PTH)
• Pregnancy test (women of childbearing age)
• FBC

Every 6 months (stable patient):

• Lithium level
• Renal function
• Thyroid function
• Calcium (annually minimum)

After every dose change: Recheck lithium level 5-7 days later

MNEMONIC 6: Lithium Toxicity Features: "TOXIC SALT"

TOXIC SALT

MNEMONIC 7: Valproate Side Effects: "VALPROATE"

VALPROATE

MNEMONIC 8: TRD Staging (Thase-Rush): "S-S-T-M-E"

S-S-T-M-E

MNEMONIC 9: Antidepressant Classes: "SSN-TMA"

SSN-TMA

SSRI memory for unique features, "FSPFEC":

• Fluoxetine = longest half-life (no discontinuation syndrome), CYP2D6 inhibitor
• Sertraline = safest in cardiac, breastfeeding
• Paroxetine = worst discontinuation, most anticholinergic, avoid in pregnancy
• Fluvoxamine = OCD specialist, CYP1A2 inhibitor
• Escitalopram = cleanest profile, most selective
• Citalopram = QTc at high doses, dose cap 40mg

MNEMONIC 10: SAD PERSONS: Suicide Risk Factors

SAD PERSONS

Scoring: 0-2 = outpatient, 3-4 = close follow-up, 5-6 = consider hospitalization, 7-10 = hospitalize

MNEMONIC 11: Serotonin Syndrome: "HAM" Triad

HAM Triad

MNEMONIC 12: SSRI Side Effects: "SING SAD"

SING SAD

MNEMONIC 13: Switching vs Augmentation Decision: "No Response = Switch; Partial Response = Augment"

Switch vs Augment

Top combination strategies, "California Rocket Fuel":

• Venlafaxine + mirtazapine = serotonin + norepinephrine boost from both sides
• SSRI + bupropion = serotonin + dopamine/NE

MNEMONIC 14: Lamotrigine Titration: "Slow and Low Saves Skin"

Slow and Low Saves Skin

Standard titration (NO valproate):

• Weeks 1-2: 25 mg/day
• Weeks 3-4: 50 mg/day
• Week 5: 100 mg/day
• Week 6-7: Target 200 mg/day

With VALPROATE (doubles lamotrigine levels):

• HALVE all doses: Start 12.5 mg → 25 mg → 50 mg → target 100 mg
• "Valproate = Very careful lamotrigine dosing"

With CARBAMAZEPINE (halves lamotrigine levels):

• May need HIGHER target doses (300-400 mg)

MNEMONIC 15: Good vs Poor Prognosis in BPAD: "LATE GOOD vs EARLY BAD"

LATE GOOD vs EARLY BAD

Good prognosis, "LATE GOOD":

• Late onset
• Adherence to treatment
• Typical euphoric mania (not mixed)
• Episodes few in number
• Good inter-episode functioning
• One mood pole predominant (not mixed)
• Outside support (social network)
• Disorder without psychosis

Poor prognosis, "EARLY BAD":

• Early onset (<25 years)
• Abuse of substances (comorbid)
• Rapid cycling
• Lack of compliance
• Years of illness (chronicity)
• Bizarre psychotic features (mood-incongruent)
• Associated personality disorder
• Depressive predominance with residual symptoms

MNEMONIC 16: Bipolar Depression: "NO Antidepressant Monotherapy!" (NOAM)

NOAM

What TO use, "QLLOC":

• Quetiapine (BOLDER trials, 300mg)
• Lithium (also anti-suicidal)
• Lamotrigine (better for prevention)
• OFC (olanzapine-fluoxetine combination)
• Cariprazine / Lurasidone (newer options)

What NOT to do:

• NO antidepressant monotherapy (manic switch risk)
• NO TCAs/venlafaxine if adding antidepressant (higher switch risk)
• If antidepressant must be used: SSRI or bupropion + mood stabilizer, SHORT course

MNEMONIC 17: Depression Rating Scales: "How Many Patients Burned out?"

How Many Patients Burned out?

MNEMONIC 18: Mania vs Hypomania: "Duration, Destruction, Delusions"

Duration, Destruction, Delusions

MNEMONIC 19: Drugs That Precipitate Lithium Toxicity: "DNATA"

DNATA

MNEMONIC 20: Discontinuation Syndrome Features: "FINISH"

FINISH

High-Yield Comparisons

TABLE 1: Bipolar I vs Bipolar II vs Cyclothymia

Swipe to compare →

TABLE 2: Mania vs Hypomania

TABLE 3: Unipolar Depression vs Bipolar Depression: Clinical Clues

TABLE 4: Lithium vs Valproate vs Carbamazepine vs Lamotrigine

TABLE 5: SSRIs vs SNRIs vs TCAs vs MAOIs

TABLE 6: TRD Staging: Thase-Rush and MGH Models

Thase-Rush Model

MGH Staging Method

Comparison

TABLE 7: Pseudodementia vs Dementia

TABLE 8: Normal Grief vs Major Depression vs Prolonged Grief Disorder

TABLE 9: Depression Rating Scales

Additional scales worth knowing:

• YMRS (Young Mania Rating Scale): 11-item clinician-rated; gold standard for mania severity
• EPDS (Edinburgh Postnatal Depression Scale): 10-item self-report; perinatal screening
• GDS (Geriatric Depression Scale): 15/30-item self-report; yes/no format avoids somatic confounds in elderly
• C-SSRS (Columbia Suicide Severity Rating Scale): Structured clinical interview for suicide ideation + behavior

TABLE 10: Newer Antidepressants Comparison

Also notable:

• Zuranolone (Zurzuvae): Oral GABA-A PAM; FDA approved 2023 for PPD; 14-day course; first oral PPD-specific treatment
• Dextromethorphan/bupropion (Auvelity): NMDA antagonist + NDRI; FDA approved 2022 for MDD; faster onset than traditional antidepressants
• Psilocybin: 5-HT2A agonist; breakthrough therapy designation for TRD; not yet approved; 1-2 sessions with psychotherapy support

PYQ Frequency Analysis

Executive Summary

Mood disorders rival schizophrenia as the highest-yield clinical topic with 50+ mentions across 28 sessions. Bipolar disorder and depression together guarantee at least 1-2 questions per exam. The spread is roughly equal between bipolar and depression, with pharmacotherapy dominating.

Topic-Level Frequency

Swipe to compare →

Must-Prepare PYQ Templates

1. "Pharmacological management of bipolar disorder.", perennial
2. "Course and outcome of BPAD.", perennial
3. "Classify BPAD. Recent advances in treatment.", perennial
4. "Lithium, mechanism, monitoring, side effects, toxicity.", perennial
5. "Define TRD. Staging. Management strategies.", perennial
6. "Depression in the elderly, features, differential, management.", perennial
7. "Suicide, risk factors, assessment, prevention strategies.", perennial
8. "Newer antidepressants. Esketamine.", emerging
9. "Genetics of bipolar disorder.", moderate
10. "Persistent mood disorders.", occasional

Analysis based on PG exams Dec 2011, Jun 2025 + PG exams 2013-2022.

Quick Review

Vignette 1: First Episode Mania

Case:

A 22-year-old male engineering student is brought by his parents with a 10-day history of decreased sleep (3-4 hours, feels well-rested), talking excessively about starting multiple business ventures, spending his semester's tuition fees on stock trading, and confrontational behavior with faculty. He has no prior psychiatric history. He believes he has "cracked the code to becoming a billionaire" and is irritable when challenged.

Q1. What is the most likely diagnosis? Justify with diagnostic criteria.

Answer:Bipolar I Disorder, current episode manic, severe, with possible mood-congruent psychotic features (grandiose delusions). Criteria met: (1) Elevated/expansive and irritable mood with increased energy for >7 days; (2) DIGFAST symptoms present, Decreased sleep need (S), Grandiosity (G), Talkativeness/pressured speech (T), Activity increase (A), Indiscretion/reckless spending (I); (3) Marked functional impairment (academic, financial); (4) No substance use indicated. The "cracking the code" belief may represent a grandiose delusion if firmly held despite evidence.

Q2. Outline your initial management plan.

Answer:

1. Safety assessment: Assess for aggression risk, suicidality, capacity for informed consent
2. Investigations: CBC, RFT, LFT, TFT (rule out hyperthyroidism), blood glucose, urine drug screen, HIV/VDRL (if indicated), ECG
3. Acute pharmacotherapy: Atypical antipsychotic (olanzapine 10-15mg or risperidone 2-4mg) for rapid symptom control + mood stabilizer (lithium 600-900mg or valproate 750-1000mg). Short-term benzodiazepine (lorazepam 2-4mg/day) for agitation and insomnia
4. Inpatient admission given severity and functional impairment
5. Psychoeducation for family regarding illness, treatment, and prognosis once acute phase stabilizes

Q3. What are the poor prognostic factors in this case?

Answer:Early onset (22 years), potential psychotic features (mood-congruent grandiosity if delusional), first episode already showing significant impairment. However, no substance use and family brought him early (supportive family) are positive. Adherence will be the key modifiable factor, young males are at highest risk for non-adherence once they feel better.

Vignette 2: Bipolar Depression Trap

Case:

A 34-year-old woman presents with persistent low mood, hypersomnia (sleeping 12-14 hours/day), increased appetite with 6 kg weight gain over 2 months, leaden paralysis, and difficulty functioning at work. She has had two prior "depressive episodes" at ages 25 and 29, each treated with SSRIs with initial improvement but subsequent worsening and "irritable episodes." Her mother has bipolar disorder.

Q1. What diagnosis should you strongly consider, and why?

Answer:Bipolar II Disorder, current episode depressive, with atypical features. Red flags for bipolarity: (1) Atypical depression features (hypersomnia, hyperphagia, leaden paralysis); (2) Early onset of depressive episodes (age 25); (3) Family history of bipolar disorder in first-degree relative; (4) Past "irritable episodes" following SSRI treatment, likely unrecognized hypomanic episodes or antidepressant-induced mood destabilization; (5) Recurrent episodes with poor sustained response to SSRIs. Screen formally with MDQ or HCL-32. Take detailed history of past mood elevations, including collateral from family.

Q2. What is the critical treatment error to avoid?

Answer:Antidepressant monotherapy. This patient has likely been repeatedly destabilized by SSRI monotherapy (the "irritable episodes" were probably antidepressant-induced hypomania or mixed features). In bipolar depression, antidepressant monotherapy carries risks of: (1) Manic/hypomanic switch; (2) Mixed state induction; (3) Rapid cycling induction; (4) Cycle acceleration. First-line treatment: quetiapine 300mg, OR lithium, OR lamotrigine, OR lurasidone. If antidepressant is added, it MUST be with mood stabilizer cover, using SSRI or bupropion (not SNRI/TCA), for the shortest effective duration.

Q3. What maintenance strategy would you recommend?

Answer:Lamotrigine (effective for preventing depressive relapses in BP-II, which is the predominant polarity), titrated slowly (25mg weeks 1-2, 50mg weeks 3-4, target 200mg by week 6-7). Alternatively, lithium (also provides anti-suicidal benefit). Quetiapine if used acutely can be continued for maintenance. Long-term psychoeducation and social rhythm therapy (IPSRT) as adjuncts. Monitor for any hypomanic switches. Indefinite maintenance given 3+ episodes.

Vignette 3: Lithium Toxicity

Case:

A 48-year-old man with Bipolar I Disorder on lithium 900mg/day for 3 years (stable, level 0.8 mEq/L last checked 2 months ago) presents with 3 days of vomiting and diarrhea due to gastroenteritis. Today he is drowsy, has a coarse tremor, slurred speech, and unsteady gait. His wife reports increasing confusion over the past 24 hours.

Q1. What is your immediate clinical concern and what investigations would you order?

Answer:Lithium toxicity precipitated by dehydration from gastroenteritis. The clinical features (coarse tremor replacing fine, dysarthria, ataxia, confusion) correspond to moderate toxicity (expected level 2.0-2.5 mEq/L). Investigations: (1) STAT serum lithium level; (2) Serum creatinine and eGFR (assess renal function); (3) Serum electrolytes (Na, K, dehydration-related derangements); (4) CBC; (5) ECG (cardiac effects of toxicity); (6) Blood glucose (exclude hypoglycemia as contributing factor).

Q2. Outline the management of this patient step by step.

Answer:

1. Stop lithium immediately
2. IV normal saline 0.9%, aggressive rehydration (200-300 mL/hour initially, titrate to clinical response and urine output); corrects dehydration AND enhances renal lithium excretion
3. Monitor lithium levels every 2-4 hours until consistently declining
4. Monitor renal function and electrolytes serially
5. Neurological monitoring, GCS, reflexes, seizure watch
6. ECG monitoring, continuous cardiac telemetry
7. Antiemetics for ongoing vomiting (ondansetron, avoid metoclopramide if possible in psychiatric patients)
8. Hemodialysis criteria: If lithium level >2.5 mEq/L with these severe symptoms (ataxia, confusion, dysarthria), hemodialysis is indicated. Also indicated if level >4.0 (regardless of symptoms), or if renal failure develops, or if clinical deterioration despite supportive care
9. Post-dialysis: Monitor for rebound (lithium redistributes from tissue compartments; repeat level 6-8 hours post-dialysis; may need repeat dialysis)
10. Once recovered: Reintroduce lithium at lower dose after complete recovery; consider whether valproate or alternative mood stabilizer more appropriate given toxicity history. Educate extensively about fluid intake, sick day rules, and drugs to avoid (NSAIDs, dehydration)

Q3. What are the "sick day rules" you would educate this patient about to prevent recurrence?

Answer:(1) If vomiting, diarrhea, or fever develop: maintain fluid intake, drink extra water; (2) If unable to keep fluids down for >24 hours: STOP lithium and seek medical attention; (3) Avoid NSAIDs (ibuprofen, naproxen); use paracetamol for pain/fever; (4) Avoid new medications without checking with prescriber (especially ACE inhibitors, ARBs, thiazides); (5) Avoid excessive sweating without fluid replacement (hot weather, intense exercise); (6) Do not reduce salt intake without medical advice; (7) Carry a lithium alert card; (8) Know early toxicity signs: increased tremor, nausea, diarrhea, drowsiness, stop lithium and contact doctor if these develop.

Vignette 4: Treatment-Resistant Depression Workup

Case:

A 42-year-old school teacher presents with persistent depressive symptoms for 18 months. She has tried escitalopram 20mg for 12 weeks (minimal improvement), then duloxetine 120mg for 10 weeks (slight improvement in energy but mood unchanged). She reports pervasive low mood, anhedonia, insomnia, fatigue, concentration difficulty, and passive suicidal ideation ("I wish I wouldn't wake up"). She is adherent to medications. No substance use.

Q1. Does this patient meet criteria for TRD? Stage the resistance.

Answer:Yes, this meets TRD criteria: failure of 2 adequate antidepressant trials from different classes (SSRI: escitalopram 20mg x 12 weeks; SNRI: duloxetine 120mg x 10 weeks) at adequate doses for adequate duration with confirmed adherence. Thase-Rush staging: Stage II (failed SSRI + failed different class). MGH score: 2 points (2 failed adequate trials). Before confirming TRD, rule out pseudo-resistance: (1) Confirm adherence (serum levels if available); (2) Screen for bipolarity (MDQ, clinical history); (3) Screen for comorbidities (thyroid, B12, anemia, diabetes, chronic pain, substance use, sleep apnea); (4) Assess personality pathology; (5) Assess psychosocial stressors.

Q2. Outline the next steps in her management algorithm.

Answer:Given PARTIAL response to duloxetine (slight energy improvement):

1. Augmentation preferred (partial response = augment; no response = switch)
2. First-line augmentation: Lithium (0.6-0.8 mEq/L, response expected 2-4 weeks) OR atypical antipsychotic (aripiprazole 2-5mg is best-tolerated; alternatives: quetiapine 50-150mg, brexpiprazole 1-2mg)
3. If lithium/atypical augmentation fails: Try T3 augmentation (liothyronine 25-50 mcg/day even if euthyroid)
4. If augmentation fails: Combination strategy, add mirtazapine to duloxetine ("California rocket fuel" variant) or switch entirely to venlafaxine + mirtazapine
5. If combinations fail: Esketamine (intranasal, with oral antidepressant), FDA approved for TRD
6. If above fails: ECT referral (especially given passive suicidal ideation)
7. Concurrent: Psychotherapy (CBT or CBASP for chronic depression); address sleep hygiene; graded exercise

Q3. The patient asks about ketamine clinics she read about online. How do you counsel her?

Answer:Esketamine (Spravato) is the FDA-approved form for TRD, administered intranasally in certified clinical settings with 2-hour monitoring. It has strong evidence for rapid antidepressant effect (hours to days) and is used with a concurrent oral antidepressant. IV ketamine (offered in private clinics) has growing evidence but is off-label for depression, not FDA-approved, variable quality control, and insurance may not cover it. Both have similar side effects: dissociation, dizziness, sedation, nausea, BP elevation. She should discuss with her psychiatrist whether she has met the criteria to warrant esketamine (failed >= 2 adequate trials, which she has). IV ketamine clinics vary in quality; ensure any clinic has psychiatric oversight, monitoring protocols, and a plan for maintenance treatment.

Vignette 5: Elderly Depression vs Dementia

Case:

A 72-year-old retired professor is brought by his son with a 3-month history of forgetfulness, social withdrawal, poor appetite with 5 kg weight loss, and loss of interest in reading (his lifelong passion). When asked about his memory, he says "I can't remember anything anymore. My brain is finished." He appears sad, makes poor eye contact, and repeatedly answers "I don't know" to cognitive screening questions. His wife died 6 months ago.

Q1. What is your differential diagnosis, and which diagnosis is most likely?

Answer:Differential: (1) Major Depressive Disorder (most likely), presenting as pseudodementia; (2) Dementia (Alzheimer's or vascular); (3) Prolonged grief disorder; (4) Medical cause (hypothyroidism, B12 deficiency, cerebral pathology). Pseudodementia is most likely because: (a) Relatively acute onset (3 months) with dateable precipitant (wife's death); (b) Patient emphasizes cognitive deficits ("I can't remember anything") rather than minimizing them; (c) "Don't know" answers on testing (poor effort rather than genuine failure); (d) Prominent vegetative symptoms (appetite, weight loss, anhedonia); (e) Sad affect with loss of interest in previously valued activities.

Q2. How would you systematically differentiate pseudodementia from early dementia?

Answer:

1. Cognitive testing: Apply MMSE/MoCA, in pseudodementia, patient gives up easily, says "I don't know," scores may fluctuate; in dementia, patient tries hard, near-miss answers, more consistent pattern of deficit
2. Detailed history (from son): Onset (acute vs gradual), temporal relationship to bereavement, any confabulation, any language decline, any getting lost, any personality change
3. Formal neuropsychological testing: Inconsistent performance in pseudodementia; consistent pattern of decline in dementia
4. Investigations: TFT, B12, folate, CBC, ESR/CRP, RFT, LFT, blood glucose, VDRL, calcium, urine analysis
5. Neuroimaging: MRI brain, assess for hippocampal atrophy (dementia), white matter hyperintensities (vascular depression), cortical atrophy
6. Depression-specific scales: GDS (Geriatric Depression Scale), HAM-D
7. Therapeutic trial: If depression suspected, start antidepressant; improvement in cognition supports pseudodementia
8. Caveat: Pseudodementia increases risk of developing true dementia (30-50% within 5 years); longitudinal follow-up essential

Q3. How would you manage this patient?

Answer:

1. Pharmacotherapy: SSRI first-line, escitalopram 5mg initially, titrate to 10-20mg ("start low, go slow, but go"); alternatively, mirtazapine 7.5-15mg at bedtime if insomnia, poor appetite, and weight loss are prominent (appetite-stimulating, sedating)
2. Avoid: TCAs (anticholinergic effects in elderly, confusion, falls, urinary retention, cardiac risk); benzodiazepines (falls, paradoxical confusion, dependence)
3. Monitor: Sodium level at 1-2 weeks (SSRI-induced hyponatremia risk higher in elderly); response assessment at 4-6 weeks
4. Psychotherapy: Supportive therapy, grief counseling; CBT adapted for elderly; behavioral activation
5. ECT: Consider if severe (significant weight loss with nutritional compromise), suicidal, or medication-refractory; safe and effective in elderly
6. Social interventions: Engage son and family; assess social isolation; day center or community activities; ensure basic needs met
7. Follow-up: Regular; repeat cognitive testing in 3-6 months to confirm improvement; remain vigilant for emergent dementia

Vignette 6: Peripartum Depression

Case:

A 28-year-old primigravida, 2 weeks postpartum, is brought by her husband. She has been persistently tearful, unable to bond with her baby, experiencing intrusive thoughts of harming the infant ("What if I drop the baby from the balcony?"), severe insomnia despite the baby sleeping, loss of appetite, and guilt ("I'm the worst mother"). She has no prior psychiatric history. She is breastfeeding.

Q1. What is the diagnosis? How do you differentiate from "baby blues"?

Answer:Major Depressive Disorder with peripartum onset (peripartum depression). Differentiation from baby blues:

Swipe to compare →

This patient has full MDE criteria (>2 weeks duration, persistent low mood, anhedonia, insomnia, appetite loss, guilt) with peripartum onset. The intrusive ego-dystonic thoughts of harm ("What if I drop the baby?") are consistent with peripartum depression/OCD, these are NOT psychotic and the patient is distressed by them (ego-dystonic). However, must screen for peripartum psychosis (does she hear voices? does she believe she SHOULD harm the baby? is there bizarre behavior?).

Q2. How do you assess and manage the intrusive thoughts?

Answer:The intrusive thoughts of harming the infant are ego-dystonic (she is horrified by them, not acting on them). This pattern is consistent with peripartum OCD-like phenomena (common in peripartum depression). Key assessment: (1) Are thoughts ego-dystonic (distressing) vs ego-syntonic (rational/justified)? (2) Any command hallucinations? (3) Any delusional beliefs about the baby? (4) Any history of violence? (5) Is she avoiding the baby out of fear (protective behavior, actually a GOOD sign of intact maternal concern)?

If ego-dystonic with no psychotic features: reassure that intrusive thoughts are common and do NOT indicate danger. They indicate anxiety and hypervigilance, not intent. Support adequate supervision of mother-infant dyad without separating them (separation worsens bonding and depression).

Q3. What is your treatment plan considering she is breastfeeding?

Answer:

1. Mild-moderate: CBT/IPT first-line (strong evidence in perinatal depression)
2. Moderate-severe (this patient): SSRI + psychotherapy. Sertraline preferred, lowest breast milk transfer of all SSRIs; extensive safety data in breastfeeding. Start 25-50mg, titrate to 100-150mg
3. Severe/refractory: Consider brexanolone (IV, inpatient, rapid but expensive/limited access) or zuranolone (oral, 14-day course, newer option)
4. ECT: If severe with suicidality, psychotic features, or inability to care for self/baby; safe postpartum
5. Practical: Ensure adequate sleep (partner/family to take some nighttime feeds, expressed milk or formula for one feed); social support; screen for domestic violence; EPDS screening
6. Safety: Supervise mother-infant interactions supportively (not punitively); involve family; safety plan if suicidality present
7. Avoid: Paroxetine (cardiac teratogenicity if future pregnancy), fluoxetine (higher breast milk levels), benzodiazepines (sedation in infant)

Vignette 7: Suicide Risk Assessment

Case:

A 55-year-old farmer from rural Karnataka presents to the emergency department after his family found him with a bottle of organophosphate pesticide, which he had not yet ingested. He recently lost his crop to drought, is Rs. 5 lakh in debt, his wife left him 3 months ago, and he has been drinking heavily (quarter of whisky daily for 2 months). He says "there is no point in living" and "my family would be better off without me." He appears calm and cooperative.

Q1. Perform a structured suicide risk assessment for this patient.

Answer:SAD PERSONS scoring:

• Sex: Male (+1)
• Age: 55 (+1)
• Depression: Likely present (+1)
• Previous attempt: Assess, this appears to be a first but interrupted attempt (+1 for current attempt/preparatory behavior)
• Ethanol: Active heavy use (+1)
• Rational thinking loss: Assess for psychosis (likely intact but cognitively narrowed) (+0 or +1)
• Social supports lacking: Wife left, likely isolated (+1)
• Organized plan: Had method (pesticide), had access (+1)
• No spouse: Separated (+1)
• Sickness: Assess, farming work, chronic pain? (need to assess)

Score: 7-9/10 = HIGH RISK, hospitalize.

C-SSRS assessment:

• Ideation: Active suicidal ideation with plan and intent (Level 5, most severe)
• Behavior: Preparatory act (obtained pesticide); interrupted attempt (found before ingestion)
• Frequency/duration: Likely persistent given circumstances

RED FLAGS: Calm demeanor after a near-attempt (may indicate decision made/relief at having a plan); access to lethal means (farmer = pesticides readily available); hopelessness ("no point"); perceived burdensomeness ("family better off without me", Joiner's interpersonal theory); multiple simultaneous stressors (financial, relational, substance use); Indian male farmer = high-risk demographic.

Q2. What immediate management is required?

Answer:

1. Safety: Admit to psychiatric inpatient unit; 1:1 observation; remove all means (belt, sharp objects, medications)
2. Means restriction: Counsel family to remove ALL pesticides and dangerous substances from the home and lock them securely; this is the single most effective intervention
3. Medical clearance: Assess for organophosphate exposure even if he says he didn't ingest (check for cholinergic symptoms); blood glucose, LFT, RFT
4. Assess for depression: Full mental status examination; HAM-D/PHQ-9; likely Major Depressive Disorder
5. Assess for alcohol use disorder: CAGE/AUDIT; medical detoxification if indicated (risk of withdrawal seizures)
6. Pharmacotherapy: Start SSRI (sertraline 50mg) for depression; manage alcohol withdrawal with benzodiazepine protocol if needed; consider short-term sedation for acute distress
7. Legal considerations: Under Mental Healthcare Act 2017, Section 115, attempted suicide is NOT a criminal offense; patient to be treated, not prosecuted; document this
8. Psychosocial: Social work consultation for financial counseling, legal aid for debt; connect with agricultural support schemes; family counseling

Q3. What population-level intervention is most relevant to preventing farming suicides in India?

Answer:Means restriction, specifically pesticide regulation. The Sri Lanka model demonstrated that banning the most toxic pesticides (WHO Class I) reduced national suicide rate by ~50% without increasing suicides by other methods (substitution did not fully occur). In India, the evidence supports: (1) Banning highly hazardous pesticides (HHPs), endosulfan already banned; expand to others; (2) Locked pesticide storage (community storage models); (3) Promoting less toxic alternatives (integrated pest management); (4) Training primary healthcare workers in rural areas to detect depression (mhGAP model); (5) Addressing root causes, crop insurance, debt relief, irrigation. The Pesticides Management Bill in India has been debated; implementing it would save lives.

Vignette 8: SSRI Non-Response

Case:

A 38-year-old IT professional was started on escitalopram 10mg for Major Depressive Disorder (moderate severity) 6 weeks ago. He reports "no change" in mood. He takes the medication "most days" and occasionally skips weekends. His PHQ-9 score is 18 (unchanged from baseline of 19).

Q1. Before diagnosing treatment failure, what factors should you assess?

Answer:Pseudo-resistance checklist:

1. Adherence: He admits to skipping weekends, this is intermittent non-adherence. Escitalopram has a 27-32 hour half-life; weekend skipping may significantly reduce effectiveness. Ask specifically about missed doses, pill counts, pharmacy records
2. Adequate dose: 10mg is the starting/therapeutic dose; may need optimization to 15-20mg before calling this a failure
3. Adequate duration: 6 weeks is borderline adequate; some patients respond at 8-12 weeks
4. Diagnosis review: Re-screen for bipolarity (MDQ), check for comorbidities (thyroid, B12, substance use, sleep disorder, personality pathology)
5. Psychosocial factors: Ongoing stressors? Work stress in IT sector? Relationship issues? Sleep hygiene?
6. Comorbid anxiety: May need higher dose or adjunctive treatment
7. Substance use: Screen for alcohol, cannabis, other substances

Q2. What is your management plan?

Answer:

1. Optimize current trial first: Increase escitalopram to 20mg; address adherence (psychoeducation about daily dosing, set phone reminders, identify barriers to adherence); reassess in 4 weeks
2. If still no response at 20mg after 4 additional weeks: This constitutes a true Thase-Rush Stage I failure
3. Next step, SWITCH (since no response rather than partial response): Switch to SNRI (venlafaxine XR 75mg → titrate to 150-225mg) or duloxetine (60-120mg)
4. Concurrent psychotherapy: CBT, strong evidence as adjunct; behavioral activation if initiation of CBT is delayed
5. Sleep hygiene and exercise: Both have evidence as adjuncts to pharmacotherapy
6. If partial response to SNRI: Augment with aripiprazole 2-5mg or lithium 600-900mg

Q3. He asks if he can stop medication once he feels better. How do you counsel him?

Answer:After remission is achieved: continue at the same dose for at least 6-12 months (continuation phase) to prevent relapse. This is his first episode, so after 6-12 months of sustained remission, gradual taper over 4-8 weeks is reasonable. If he has recurrent episodes (2+ episodes, or 1 severe episode with suicidality/psychosis), maintenance treatment may be indefinite. Abrupt discontinuation risks: (1) Relapse; (2) Discontinuation syndrome (dizziness, sensory disturbances, GI upset, less common with escitalopram vs paroxetine/venlafaxine but still possible). Educate that antidepressants are NOT addictive (common misconception) but should not be stopped abruptly.

Vignette 9: Mixed Features

Case:

A 30-year-old woman with known Bipolar I Disorder presents with 5 days of elevated mood, decreased sleep (4 hours/night, feels energized), grandiose plans to start a restaurant chain, and pressured speech. However, she simultaneously reports feeling "desperately sad inside," frequent crying episodes, and suicidal thoughts. She says "I have all this energy but I want to die."

Q1. What DSM-5 specifier applies to this presentation?

Answer:Manic episode with mixed features. She meets full criteria for a manic episode (elevated mood, decreased sleep need, grandiosity, pressured speech, >7 days if criteria have been met). The mixed features specifier requires >= 3 concurrent depressive symptoms during the manic episode: (1) Depressed mood ("desperately sad inside"); (2) Diminished interest is not clearly mentioned but crying episodes suggest; (3) Suicidal ideation. Three depressive symptoms during mania qualifies for the "with mixed features" specifier.

Clinical significance: Mixed features = HIGHER suicide risk than pure mania. The combination of manic energy/impulsivity with depressive hopelessness/suicidality is particularly dangerous.

Q2. How does this presentation change your treatment approach compared to pure mania?

Answer:Key treatment differences:

1. Avoid antidepressants entirely, worse outcomes in mixed states
2. Lithium may be LESS effective in mixed presentations compared to pure euphoric mania
3. Valproate often preferred, better evidence for mixed states than lithium
4. Atypical antipsychotics: Olanzapine, quetiapine, aripiprazole, asenapine all have evidence for mixed mania
5. Combination therapy often needed earlier: Mood stabilizer + atypical antipsychotic
6. Higher suicide monitoring: Mixed features = highest suicide risk in bipolar; consider inpatient admission; 1:1 observation if actively suicidal; remove means

Q3. What is the suicide risk profile of this patient?

Answer:VERY HIGH. Risk factors: (1) Active suicidal ideation during a mood episode; (2) Mixed features (energy + impulsivity to act on suicidal thoughts); (3) Female (more attempts); (4) Known bipolar disorder (15-20x general population suicide rate); (5) Current acute episode. Protective factor assessment needed: children? social support? religious beliefs? Immediate safety planning required. This patient should be hospitalized until the mixed episode resolves. The lethality of mixed states is that patients have the depressive wish to die AND the manic energy to act on it, the most dangerous combination in all of psychiatry.

Vignette 10: Rapid Cycling

Case:

A 40-year-old woman with Bipolar II Disorder has had 6 mood episodes in the past 12 months (4 depressive, 2 hypomanic). She is currently on lithium 900mg/day (level 0.7 mEq/L) and sertraline 100mg/day. Her last TSH was 8.2 mIU/L (elevated; reference 0.5-4.5).

Q1. What pattern does this represent, and what are the likely contributing factors?

Answer:Rapid cycling, defined as >= 4 mood episodes in 12 months. She has had 6 episodes, qualifying clearly. Contributing factors in this case:

1. Antidepressant use (sertraline), classic trigger for rapid cycling; antidepressants can accelerate cycle frequency, particularly in bipolar
2. Hypothyroidism (TSH 8.2), unrecognized or undertreated hypothyroidism is a well-established risk factor for rapid cycling and medication resistance
3. Female sex, rapid cycling is 2-3x more common in women
4. BP-II, rapid cycling is more common in BP-II than BP-I

Q2. What immediate changes would you make to her treatment?

Answer:

1. Taper and discontinue sertraline, antidepressant withdrawal is the first and most critical intervention in rapid cycling. Taper over 2-4 weeks
2. Treat hypothyroidism, start levothyroxine (50-75 mcg initially; titrate to normalize TSH). This alone may significantly reduce cycling. Target TSH in lower normal range
3. Optimize/switch mood stabilizer: Lithium may be LESS effective in rapid cycling. Options: (a) Add valproate to lithium (combination therapy); or (b) Switch to valproate monotherapy if lithium has been clearly ineffective; or (c) Lamotrigine addition for depression prevention (given 4 depressive vs 2 hypomanic episodes, her predominant polarity is depressive)
4. Monitor closely, mood charting (daily mood diary) is essential for tracking response

Q3. After 3 months, thyroid is normalized, sertraline discontinued, and she is on lithium + valproate. She develops a depressive episode. How do you manage it?

Answer:Bipolar depression in a rapid-cycling patient, this is among the hardest presentations to treat:

1. Do NOT reintroduce antidepressants, high risk of re-inducing rapid cycling
2. First-line: Quetiapine 300mg (evidence for bipolar depression; won't destabilize cycling)
3. Alternative/adjunct: Lamotrigine (titrate slowly; better for prevention but can be trialed acutely)
4. Lurasidone: FDA approved for bipolar depression; add to lithium/valproate
5. Optimize existing mood stabilizers: Ensure valproate level in upper therapeutic range
6. If refractory: ECT (effective in bipolar depression, no cycling risk)
7. Psychotherapy: CBT adapted for bipolar, IPSRT for rhythm stabilization
8. Lifestyle: Sleep hygiene (critical in rapid cycling, any sleep disruption can trigger episodes), regular social rhythms, exercise

Vignette 11: Valproate in Women of Childbearing Age

Case:

A 26-year-old newly married woman with Bipolar I Disorder has been stable on valproate 1000mg/day for 3 years (no episodes since starting). She comes for preconception counseling as she and her husband wish to start a family within the year.

Q1. What are the teratogenic risks of valproate, and why is this an ethical dilemma?

Answer:Valproate teratogenicity:

1. Neural tube defects: 1-2% risk (10x general population), spina bifida most common
2. Neurodevelopmental effects: Average 8-9 IQ point reduction in children exposed in utero (NEAD study); higher rates of autism spectrum disorder, developmental delay, and learning disabilities
3. Other malformations: Craniofacial, cardiac, limb defects
4. Dose-dependent: Higher doses = greater risk; no established safe threshold

The ethical dilemma: She has been stable for 3 years on this medication. Switching introduces: (1) Risk of relapse during switch; (2) Risk of relapse during pregnancy if alternative is less effective; (3) Manic or depressive episodes during pregnancy are themselves harmful to fetus and mother. However, continuing valproate exposes the fetus to serious, well-documented harm. Recent EMA/MHRA guidelines effectively contraindicate valproate in women of childbearing age unless no alternative exists and a Pregnancy Prevention Programme is in place. The principle of informed consent and shared decision-making is critical.

Q2. What is your management plan?

Answer:

1. Switch medication BEFORE conception, do NOT wait until pregnancy is confirmed (NTD risk is highest in first 4-6 weeks, often before pregnancy is recognized)
2. Switch to safer mood stabilizer: Lamotrigine is the preferred option, best safety data in pregnancy (minimal teratogenicity); effective for bipolar maintenance, especially depression prevention. Titrate lamotrigine UP while tapering valproate DOWN (cross-titration). Note: valproate inhibits lamotrigine metabolism, so lamotrigine levels will RISE as valproate is withdrawn
3. Alternative: Lithium, effective for maintenance; Ebstein's anomaly risk is ~0.1% (lower than historically cited); requires level monitoring through pregnancy; dose adjustments needed (GFR increases in pregnancy → clearance increases → may need dose increase; then after delivery → GFR drops → risk of toxicity); fetal echocardiography at 16-20 weeks
4. High-dose folic acid: 5mg/day (not standard 400mcg), start at least 1 month before conception; continue through first trimester
5. Contraception until switch is complete and stable (3-6 months on new medication without relapse before attempting conception)
6. Multidisciplinary team: Psychiatrist + obstetrician + genetic counselor
7. Monitor closely during switch and pregnancy, pregnancy is a high-risk period for relapse

Q3. She asks if she can "just stop all medications during pregnancy." How do you counsel her?

Answer:Stopping all medication is NOT recommended for Bipolar I Disorder. Relapse rates off medications during pregnancy are very high, up to 70% (Viguera et al., 2007). A manic episode during pregnancy poses serious risks: poor self-care, risky behavior, substance use, impaired judgment, nonadherence to prenatal care, and postpartum psychosis risk. A depressive episode risks: poor nutrition, self-harm/suicide, impaired bonding, preeclampsia association. The goal is to find the safest effective medication, not to be medication-free. Lamotrigine offers the best benefit-risk ratio. The decision should be collaborative, fully informed, and documented.

Vignette 12: Seasonal Affective Disorder

Case:

A 35-year-old software developer relocated from Bangalore to London 2 years ago. For both winters since the move, she has experienced low mood beginning in October, resolving spontaneously by March. Symptoms include hypersomnia (sleeping 11-12 hours), carbohydrate craving, weight gain (4 kg each winter), fatigue, and social withdrawal. Her summers are entirely normal. She had no such symptoms in Bangalore.

Q1. What is the diagnosis and what is the pathophysiology?

Answer:Major Depressive Disorder, recurrent, with seasonal pattern (Seasonal Affective Disorder, SAD). Criteria: (1) Regular temporal relationship between onset of depressive episodes and a particular time of year; (2) Full remissions at a characteristic time (spring); (3) >= 2 major depressive episodes with seasonal pattern in last 2 years; (4) Seasonal episodes substantially outnumber non-seasonal episodes over lifetime.

Pathophysiology:

• Reduced sunlight exposure → decreased retinal light input → altered melatonin secretion (prolonged melatonin phase) + reduced serotonin synthesis (5-HT production is light-dependent)
• Phase-delay hypothesis: circadian rhythm shifts later relative to the light-dark cycle
• Latitude-dependent: higher prevalence at northern latitudes (explains onset after moving from Bangalore ~13N to London ~51N)
• Atypical depression features (hypersomnia, hyperphagia, carbohydrate craving) are characteristic

Q2. What are the first-line treatment options?

Answer:

1. Light therapy (phototherapy): FIRST-LINE for SAD. 10,000 lux bright light box for 30 minutes each morning (upon waking). Position 16-24 inches from face, eyes open but not staring directly at light. Response typically within 1-2 weeks. Continue through the winter season. Evidence-based; comparable efficacy to SSRIs for seasonal depression
2. SSRIs: Fluoxetine or sertraline, effective for SAD; can be used alone or combined with light therapy; bupropion XL approved for PREVENTION of seasonal depression (start in autumn before symptom onset)
3. CBT adapted for SAD: Evidence-based; may have more durable effects than light therapy (lower relapse rate in subsequent winter)
4. Lifestyle: Regular exercise, maximize outdoor daylight exposure (walk during lunch), maintain social activities, vitamin D supplementation (often deficient at high latitudes)

Q3. She asks about prevention for next winter. What do you advise?

Answer:(1) Begin light therapy prophylactically in September/October (before symptoms onset); (2) Bupropion XL 150-300mg starting in early autumn, FDA approved for prevention of seasonal MDE; (3) Maintain exercise routine through autumn-winter; (4) Vitamin D supplementation (1000-2000 IU daily through winter); (5) Consider a dawn simulator alarm clock (gradually increases light in bedroom before waking); (6) If considering relocation back to India, this would effectively treat the condition; (7) Monitor mood with a brief weekly self-rating (PHQ-2 or mood diary) to catch early symptoms.

Vignette 13: Psychotic Depression

Case:

A 58-year-old woman presents with 6 weeks of severe depression, pervasive low mood, total anhedonia, psychomotor retardation (barely moves, speaks in whispers), 8 kg weight loss from food refusal, and early morning awakening at 3 AM. She believes her internal organs are "rotting away" and that she is already dead. She says the police are coming to arrest her for crimes she committed in a past life.

Q1. What is the diagnosis and what specific features are present?

Answer:Major Depressive Disorder, severe, with mood-congruent psychotic features. Specific features:

1. Melancholic features: Total anhedonia, distinct quality of depressed mood, psychomotor retardation, early morning awakening, significant weight loss, worse in morning (likely)
2. Nihilistic delusions (Cotard syndrome): Believes organs are "rotting" and she is "already dead", Cotard's delusion/syndrome is pathognomonic of psychotic depression; involves nihilistic delusions about the body, existence, or the world
3. Delusions of guilt: Believes she committed crimes, mood-congruent guilt delusion
4. Persecutory ideation: Believes police will arrest her, this could be mood-congruent (punishment for perceived crimes) or mood-incongruent (if unrelated to guilt theme)
5. Nutritional compromise: 8 kg weight loss from food refusal, medical emergency

Q2. What is the optimal treatment for this presentation?

Answer:Psychotic depression requires COMBINATION treatment or ECT, antidepressant monotherapy is insufficient:

1. ECT, strongest recommendation: For this patient specifically, ECT is arguably the FIRST-LINE treatment because: (a) Psychotic depression responds best to ECT (>80% response rate); (b) Nutritional compromise is a clear indication; (c) Fastest onset of all treatments; (d) Cotard syndrome responds particularly well to ECT. Bilateral placement preferred for psychotic depression.

1. Pharmacotherapy (if ECT not immediately available): Antidepressant + antipsychotic combination. Examples: (a) Venlafaxine + olanzapine (evidence from Meyers et al., STOP-PD study); (b) Sertraline + olanzapine; (c) TCA (nortriptyline) + antipsychotic. Antidepressant alone is INFERIOR to combination for psychotic depression.

1. Supportive care: IV fluids and nutrition if refusing oral intake; 1:1 nursing observation (suicide risk very high in psychotic depression); monitor medical status (dehydration, electrolytes, muscle wasting).

Q3. After successful ECT treatment, she remits. What is the maintenance plan?

Answer:(1) Continue antidepressant + antipsychotic for at least 6-12 months post-remission (STOP-PD II study showed discontinuing olanzapine led to high relapse rates); (2) Maintenance ECT: weekly → biweekly → monthly, especially if she has relapsed on pharmacotherapy before; (3) Gradual taper of antipsychotic can be attempted after 4-6 months if stable, with close monitoring for relapse; (4) If antipsychotic discontinued, maintain antidepressant indefinitely (given severity of this episode); (5) Longitudinal monitoring, psychotic depression has high recurrence rate; educate family about early warning signs.

Vignette 14: Lamotrigine Rash Scenario

Case:

A 32-year-old man with Bipolar II Disorder was started on lamotrigine 2 weeks ago for maintenance (currently on 25mg/day, titrating per protocol). He calls today reporting a "rash on his arms" that appeared yesterday. He has no fever, no mucosal involvement, no pain, and the rash is described as a few scattered, non-confluent papules.

Q1. How do you assess whether this rash is benign or a harbinger of Stevens-Johnson Syndrome?

Answer:Critical assessment, this is a medical decision, not a reassurance call:

In this patient: no fever, no mucosal involvement, no pain, non-confluent papules, likely benign. HOWEVER, the standard of care is conservative.

Q2. What is your management recommendation?

Answer:

1. Default position: STOP lamotrigine until the rash is formally evaluated. This is the standard recommendation, when in doubt, stop. The risk of missing early SJS far outweighs the inconvenience of stopping a medication that can be restarted.
2. See the patient in person TODAY or within 24 hours, rash cannot be adequately assessed by phone/telemedicine alone
3. Examine for: Mucosal lesions (mouth, eyes, genitals), skin tenderness, Nikolsky sign, confluence, facial involvement, blistering
4. If benign rash confirmed: May cautiously restart lamotrigine at a LOWER dose (12.5mg) with even slower titration. Some clinicians add antihistamine
5. If any concerning features: Do NOT restart lamotrigine. Switch to alternative (lithium, quetiapine). Dermatology consultation
6. If SJS confirmed: Emergency hospitalization, dermatology/burns unit, supportive care (similar to burns management), stop ALL potential causative drugs
7. Educate patient: "If the rash spreads, if you develop mouth sores, eye irritation, fever, or if it hurts, go to the emergency department immediately"

Q3. What factors increase the risk of lamotrigine-induced SJS?

Answer:(1) Rapid titration, the single most important modifiable risk factor; slower = safer; (2) Concurrent valproate, doubles lamotrigine levels; if on valproate, must halve the lamotrigine titration rate; (3) Young age, children and adolescents at higher risk; (4) History of rash with other anticonvulsants; (5) HLA-B*1502 allele, same allele associated with carbamazepine SJS; some evidence for lamotrigine too, especially in Asian populations; (6) Higher starting dose; (7) Immune activation, concurrent infection may increase risk. Risk is highest in the first 8 weeks and essentially drops to baseline after 6 months of stable dosing.

Vignette 15: Serotonin Syndrome from Drug Interaction

Case:

A 45-year-old woman on fluoxetine 40mg for Major Depressive Disorder visits an orthopedic surgeon for back pain. The surgeon prescribes tramadol 50mg TDS. Three days later, she presents to the ER with agitation, confusion, profuse sweating, tachycardia (HR 120), blood pressure 160/95, temperature 38.8C, bilateral lower limb clonus, hyperreflexia, and myoclonic jerks. Her pupils are dilated.

Q1. What is the diagnosis, and what caused it?

Answer:Serotonin syndrome caused by the combination of fluoxetine (SSRI, serotonin reuptake inhibitor) + tramadol (opioid with serotonin reuptake inhibition properties). Fluoxetine is also a potent CYP2D6 inhibitor, which would further increase tramadol levels (tramadol is metabolized by CYP2D6).

Hunter Criteria assessment:

• Serotonergic agent: YES (fluoxetine + tramadol)
• Inducible clonus + agitation + diaphoresis: YES
• Diagnosis confirmed.

Key features present: Mental status change (agitation, confusion), autonomic instability (tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis), neuromuscular hyperactivity (clonus, hyperreflexia, myoclonus). The classic triad: HAM = Hyperactivity (neuromuscular), Autonomic instability, Mental status changes.

Q2. How do you differentiate this from Neuroleptic Malignant Syndrome (NMS)?

Answer:

The presence of CLONUS (especially lower limb), hyperreflexia, and rapid onset with serotonergic drugs clinches serotonin syndrome. NMS would show rigidity and bradyreflexia.

Q3. What is the management of this patient?

Answer:

1. Stop ALL serotonergic agents immediately, discontinue both fluoxetine and tramadol
2. Supportive care: IV fluids (hydration), continuous monitoring (HR, BP, temperature, SpO2), cooling measures for hyperthermia (cooling blankets, ice packs, tepid sponging; avoid antipyretics, fever is from muscle activity, not hypothalamic)
3. Benzodiazepines: Lorazepam 1-2mg IV for agitation and to reduce neuromuscular hyperactivity
4. Cyproheptadine: Specific antidote, 5-HT2A antagonist. Loading dose 12mg PO/NG, then 4-8mg every 2 hours until improvement (max 32mg/day). Oral/NG only (no parenteral form)
5. If severe (temperature >41.1C, seizures, arrhythmias): ICU admission, intubation, neuromuscular paralysis (non-depolarizing agent, NOT succinylcholine as it may worsen hyperkalemia from rhabdomyolysis), mechanical ventilation
6. Monitor: CK (rhabdomyolysis risk), renal function (myoglobin nephropathy), electrolytes, coagulation (DIC risk in severe cases)
7. Expected resolution: 24-72 hours after drug discontinuation (fluoxetine has a long half-life, so may take longer)
8. Follow-up: When stable, restart antidepressant (avoid tramadol in the future); educate about drug interactions; for pain management, alternatives include paracetamol, NSAIDs, gabapentin, or non-serotonergic opioids (morphine, oxycodone have minimal serotonergic activity)
9. Systems-level learning: This was a prescribing error, the orthopedic surgeon should have checked her medication list. Advocate for electronic prescribing alerts for serotonergic drug combinations. Common dangerous combinations: SSRI/SNRI + tramadol, SSRI/SNRI + MAOI, SSRI/SNRI + linezolid, SSRI/SNRI + methylene blue, SSRI/SNRI + St. John's wort